CN107875123A - Functionalization vinblastine liposome and its application - Google Patents
Functionalization vinblastine liposome and its application Download PDFInfo
- Publication number
- CN107875123A CN107875123A CN201610854962.2A CN201610854962A CN107875123A CN 107875123 A CN107875123 A CN 107875123A CN 201610854962 A CN201610854962 A CN 201610854962A CN 107875123 A CN107875123 A CN 107875123A
- Authority
- CN
- China
- Prior art keywords
- liposome
- vinblastine
- cell
- tfr
- brain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 345
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 title claims abstract description 316
- 229960003048 vinblastine Drugs 0.000 title claims abstract description 314
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 title claims abstract description 313
- 238000007306 functionalization reaction Methods 0.000 title abstract description 102
- 238000012986 modification Methods 0.000 claims abstract description 121
- 230000004048 modification Effects 0.000 claims abstract description 105
- 210000000130 stem cell Anatomy 0.000 claims abstract description 67
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims abstract description 46
- 206010018338 Glioma Diseases 0.000 claims abstract description 40
- 208000032612 Glial tumor Diseases 0.000 claims abstract description 39
- 108050003222 Transferrin receptor protein 1 Proteins 0.000 claims abstract description 37
- 230000008499 blood brain barrier function Effects 0.000 claims abstract description 19
- 210000001218 blood-brain barrier Anatomy 0.000 claims abstract description 19
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 15
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims abstract description 9
- 108010011110 polyarginine Proteins 0.000 claims abstract description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 179
- 208000024055 brain glioblastoma Diseases 0.000 claims description 76
- 201000011609 brain glioblastoma multiforme Diseases 0.000 claims description 76
- 238000000034 method Methods 0.000 claims description 40
- 238000002360 preparation method Methods 0.000 claims description 37
- 230000014509 gene expression Effects 0.000 claims description 33
- 230000006907 apoptotic process Effects 0.000 claims description 29
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 26
- 230000006378 damage Effects 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 20
- 235000012000 cholesterol Nutrition 0.000 claims description 14
- 210000003470 mitochondria Anatomy 0.000 claims description 14
- 208000027418 Wounds and injury Diseases 0.000 claims description 12
- -1 cromoci Proteins 0.000 claims description 12
- 208000014674 injury Diseases 0.000 claims description 12
- 210000002706 plastid Anatomy 0.000 claims description 11
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 10
- 108010009306 Forkhead Box Protein O1 Proteins 0.000 claims description 10
- 239000004698 Polyethylene Substances 0.000 claims description 10
- 238000005917 acylation reaction Methods 0.000 claims description 10
- 235000010445 lecithin Nutrition 0.000 claims description 10
- 239000000787 lecithin Substances 0.000 claims description 10
- 229940067606 lecithin Drugs 0.000 claims description 10
- 102000047934 Caspase-3/7 Human genes 0.000 claims description 8
- 108700037887 Caspase-3/7 Proteins 0.000 claims description 8
- 108090000538 Caspase-8 Proteins 0.000 claims description 8
- 108090000566 Caspase-9 Proteins 0.000 claims description 8
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims description 8
- 102000055102 bcl-2-Associated X Human genes 0.000 claims description 8
- 108700000707 bcl-2-Associated X Proteins 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 8
- 229920000573 polyethylene Polymers 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical group CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 6
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 claims description 5
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 claims description 5
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims description 4
- 206010020718 hyperplasia Diseases 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- SRLOHQKOADWDBV-NRONOFSHSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] 2-(2-methoxyethoxycarbonylamino)ethyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)OCCOC)OC(=O)CCCCCCCCCCCCCCCCC SRLOHQKOADWDBV-NRONOFSHSA-M 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 238000005755 formation reaction Methods 0.000 claims description 2
- 102100026548 Caspase-8 Human genes 0.000 claims 1
- 102100026550 Caspase-9 Human genes 0.000 claims 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 1
- 125000001095 phosphatidyl group Chemical group 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 24
- 238000002474 experimental method Methods 0.000 abstract description 8
- 229920001223 polyethylene glycol Polymers 0.000 abstract description 6
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 abstract description 3
- 239000002202 Polyethylene glycol Substances 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- 239000003513 alkali Substances 0.000 description 31
- 238000011580 nude mouse model Methods 0.000 description 31
- 206010028980 Neoplasm Diseases 0.000 description 28
- 241000699660 Mus musculus Species 0.000 description 27
- 210000004556 brain Anatomy 0.000 description 21
- 201000007983 brain glioma Diseases 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 238000000574 gas--solid chromatography Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 239000000523 sample Substances 0.000 description 16
- 239000007788 liquid Substances 0.000 description 14
- 239000002504 physiological saline solution Substances 0.000 description 14
- 240000001829 Catharanthus roseus Species 0.000 description 13
- 102000008730 Nestin Human genes 0.000 description 12
- 108010088225 Nestin Proteins 0.000 description 12
- 210000005055 nestin Anatomy 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 240000002853 Nelumbo nucifera Species 0.000 description 11
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 11
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 210000005013 brain tissue Anatomy 0.000 description 10
- 238000004113 cell culture Methods 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- 239000012679 serum free medium Substances 0.000 description 10
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 9
- 229930040373 Paraformaldehyde Natural products 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 229920002866 paraformaldehyde Polymers 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 108010010803 Gelatin Proteins 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000008273 gelatin Substances 0.000 description 8
- 229920000159 gelatin Polymers 0.000 description 8
- 235000019322 gelatine Nutrition 0.000 description 8
- 235000011852 gelatine desserts Nutrition 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 7
- 102000004091 Caspase-8 Human genes 0.000 description 7
- 102000004039 Caspase-9 Human genes 0.000 description 7
- 101000928239 Homo sapiens Afamin Proteins 0.000 description 7
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 230000004900 autophagic degradation Effects 0.000 description 7
- 230000005284 excitation Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108010019160 Pancreatin Proteins 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 229940055695 pancreatin Drugs 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 5
- 108010052832 Cytochromes Proteins 0.000 description 5
- 102000018832 Cytochromes Human genes 0.000 description 5
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 5
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229920005654 Sephadex Polymers 0.000 description 5
- 239000012507 Sephadex™ Substances 0.000 description 5
- 239000013504 Triton X-100 Substances 0.000 description 5
- 229920004890 Triton X-100 Polymers 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108010033576 Transferrin Receptors Proteins 0.000 description 4
- 238000001994 activation Methods 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 230000001348 anti-glioma Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 3
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 3
- 102000000412 Annexin Human genes 0.000 description 3
- 108050008874 Annexin Proteins 0.000 description 3
- 102000011727 Caspases Human genes 0.000 description 3
- 108010076667 Caspases Proteins 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 3
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000005099 mouse brain capillary cell Anatomy 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000003625 skull Anatomy 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 2
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 101710132652 Protein O1 Proteins 0.000 description 2
- 102000002070 Transferrins Human genes 0.000 description 2
- 108010015865 Transferrins Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000001166 ammonium sulphate Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 210000001159 caudate nucleus Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 238000005553 drilling Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000002952 image-based readout Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 241000208327 Apocynaceae Species 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000019736 Cranial nerve disease Diseases 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 101001111320 Homo sapiens Nestin Proteins 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- ARCUKJFDARVQKH-UHFFFAOYSA-N [U]=O Chemical compound [U]=O ARCUKJFDARVQKH-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- BIGPRXCJEDHCLP-UHFFFAOYSA-N ammonium bisulfate Chemical compound [NH4+].OS([O-])(=O)=O BIGPRXCJEDHCLP-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000005257 cortical tissue Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000005096 hematological system Anatomy 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000005524 hole trap Effects 0.000 description 1
- 102000043377 human NES Human genes 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108010038765 octaarginine Proteins 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 238000013379 physicochemical characterization Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000079 presaturation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical class [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229960004982 vinblastine sulfate Drugs 0.000 description 1
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses functionalization vinblastine liposome and its application.The invention provides a kind of vinblastine liposome, for with functionalization material TfR binding peptide polyethylene glycol DSPE and the poly arginine modified liposome of stearyl eight, liposome after being modified, vinblastine is contained after the modification in liposome again, obtains functionalization vinblastine liposome.The experiment proves that the present invention has synthesized a kind of functionalization material TfR binding peptide polyethylene glycol DSPE (NHS PEG2000DSPE), and with it with targetting the poly arginine of material stearyl eight (stearyl R8) modification vinblastine liposome, obtain a kind of to cross over blood-brain barrier and killing glioma and its functionalization vinblastine liposome of stem cell.
Description
Technical field
The present invention relates to biological technical field, more particularly to a kind of functionalization vinblastine liposome and its application.
Background technology
Vinblastine (vinblastine, VLB) by Canadian University of Western Ontario scientist Robert Noble and
Charles Thomas extracted isolated from apocynaceae plant catharanthus roseus first in 1958, and it is a kind of double indoles types
Alkaloid, there is antitumor activity.The structural formula of vinblastine is as shown in figure 1, molecular formula is C46H58N4O9, molecular weight is
810.97, normal vitriolization salt is not soluble in water, for white or off-white color crystalline powder.
TfR binding peptide TfR-T12It is the polypeptide that sequence is THRPPMWSPVWP, includes 12 amino acid
(Thr-His-Arg-Pro-Pro-Met-Trp-Ser-Pro-Val-Trp-Pro), soluble in water and methanol, molecular weight are
1490.8。TfR-T12Polypeptide can be specifically bound with human TfR (transferrin receptor, TfR), and
Competion experiment shows that its binding site is different with the binding site of transferrins (transferrin, Tf), and this causes TfR-
T12It will not be disturbed when being combined in vivo with TfR by transferrins.Due to high on blood-brain barrier and tumour cell
Express TfR, therefore TfR-T12There is potential using value in brain targeted drug delivery system.
The poly arginine of stearyl eight (stearylated octaarginine, Stearyl-R8) be by eight arginine and
Functional material obtained by stearyl (stearyl) synthesis connection, is synthesized to obtain first by Shiroh Futaki etc..Eight gather smart ammonia
Acid can help DNA to be transfected into cell, be dramatically increased being combined rear transfection efficiency with stearyl.Stearyl-R8Energy
Help material to enter cell and be primarily due to arginine with abundant cationic species, and (especially tumour is thin for most cells
Born of the same parents) and organelle surface be in elecrtonegativity, therefore the function with targets neoplastic cells and subcellular organelle, simultaneously because stearyl
In the presence of can be plugged on the phospholipid bilayer of liposome, help liposome target tumor position.
DSPE-PEG (DSPE-PEG2000) it is that one kind is used for long circulating liposome system
Standby material, 1992 by Maruyama K etc. reported the material modification big unilamellar liposome circulated in hematological system when
Between be extended.By the DSPE-PEG of NHS group activations2000For DSPE-PEG-N-
Succinimide (NHS-PEG2000- DSPE), easily reacted with the amino on polypeptide, slough N- hydroxysuccinimidyl acyls during the course of the reaction
Imines, amido link is generated, it is easily operated.
Glioma is a kind of great brain diseases, and operative treatment difficulty is big, and radiotherapy side effect is more, and operation is controlled
Still can a small amount of brain glioblastoma cell of remaining and its stem cell after treatment or radiotherapy.In conventional chemotherapy, chemotherapeutics
It is difficult to cross over blood-brain barrier, and a small amount of medicine that can cross over blood-brain barrier is because human brain glioma stem cells have drug resistance, it is also difficult
It is clean to be removed, cause the recurrence of glioma.Therefore, how to help chemotherapeutics across blood-brain barrier, in killing brain
It is the important scientific issues to remain unsolved that the glioma of remaining and its stem cell are removed while glioma.
The content of the invention
It is an object of the present invention to provide a kind of liposome or vinblastine liposome.
Liposome provided by the invention is through TfR binding peptide-PEG2000-DSPE
Modified with the poly arginine of stearyl eight;
Vinblastine liposome provided by the invention is by the liposome and contains the catharanthus roseus in the liposome
Alkali forms;
TfR binding peptide-the PEG2000-DSPE is by TfR-T12Polypeptide and
NHS-PEG2000The product that-DSPE is obtained by acid amides key connection.
TfR-T12(Thr-His-Arg-Pro-Pro-Met-Trp-Ser-Pro-Val-Trp-Pro) purchased from the peptide life of Hefei state
Thing Science and Technology Ltd..
Another object of the present invention is to provide a kind of method for preparing above-mentioned vinblastine liposome.
Method provided by the invention, for TfR binding peptide-PEG2000-DSPE
With the poly arginine (stearyl-R of stearyl eight8) modified liposome, and vinblastine is contained and grown in the liposome
Spring flower alkali liposome.
The above method comprises the following steps:
1) TfR binding peptide-PEG2000-DSPE is prepared;
The preparation method comprises the following steps:By TfR-T12Polypeptide and NHS-PEG2000Effects of-the DSPE in catalyst
Lower carry out acylation reaction, obtains TfR binding peptide-PEG2000-DSPE;
It is above-mentioned prepare TfR binding peptide-PEG2000-DSPE method it is also specific
Comprise the following steps:After the acylation reaction step, reaction system is transferred in bag filter, is placed in deionized water thoroughly
Analysis 24 hours, solvent and unreacting material are removed, obtains TfR binding peptide-polyethylene glycol-distearoylphosphatidyl
Monoethanolamine;
The molecular cut off of the bag filter is specially 3000Da;The time of the dialysis is 24 hours.
2) with lecithin, cholesterol, TfR binding peptide-polyethylene glycol-distearoylphosphatidyl ethanol
Amine (TfR-T12-PEG2000- DSPE) and the poly arginine (stearyl-R of stearyl eight8) carry out film formation reaction, fat after being modified
Plastid, liposome after being modified;
The method of liposome specifically comprises the following steps after above-mentioned preparation modification:By lecithin, cholesterol and TfR-T12-
PEG2000- DSPE is dissolved in organic solvent, and organic solvent is removed under reduced pressure, and forms the system containing film;Ammonium sulfate is added to enter
Water-filling obtains thick liposome;Again by thick lipide supersonic, product after ultrasound is obtained, is by aperture by product after ultrasound
200nm poly- carbon ester film, filtrate are dialysed by bag filter, obtain liposome;
3) vinblastine is contained after the modification in liposome, obtains vinblastine liposome.
Above-mentioned contain vinblastine in the liposome comprises the following steps:The vinblastine methanol is molten
Solution, lysate is obtained, then liposome and the lysate are mixed, reaction, obtain vinblastine liposome.
In the above method, in step 1), the TfR-T12Polypeptide and NHS-PEG2000- DSPE molar ratio is 1:1-
3:1;
Or, the catalyst is N-methylmorpholine;
Or, the catalyst and the TfR-T12The charge ratio of polypeptide is 200 μ L:8μmol;
Or, the temperature of the acylation reaction is normal temperature, the time of acylation reaction is 48h;
Or, the acylation reaction is carried out in a solvent;
Or, the solvent is specially DMF.
In the above method, in step 2), the lecithin, cholesterol, institute's TfR binding peptide-polyethylene glycol-
DSPE and the stearyl-R8Molar ratio be 60:30:3:5.
In the above method, in step 3), the mass ratio that feeds intake of liposome is 1 after the vinblastine and the modification:20.
TfR binding peptide-polyethylene glycol-distearoylphosphatidyl the second being prepared in the above method
Hydramine is also the scope of protection of the invention;
Or liposome is also the scope of protection of the invention after the modification being prepared in the above method.
Above-mentioned TfR binding peptide-PEG2000-DSPE prepare liposome or
The application for preparing vinblastine liposome or modified liposome or modifying in vinblastine liposome is also the model of the invention protected
Enclose;
Or above-mentioned vinblastine liposome or above-mentioned TfR binding peptide-polyethylene glycol-distearyl phosphorus
Acyl monoethanolamine is being prepared with following 1) -9) application in the product of at least one function is also the scope of protection of the invention:
1) brain glioblastoma cell or its stem cell are killed;
2) brain glioblastoma cell or its stem cells hyperplasia are suppressed;
3) blood-brain barrier is crossed over;
4) brain glioblastoma cell or its stem cell apoptosis are promoted;
5) brain glioblastoma cell or the injury of mitochondria of its stem cell are promoted;
6) brain glioblastoma cell or its Stem Cell Activity oxygen level are improved;
7) brain glioblastoma cell or the micro-duct injury of its stem cell are promoted;
8) improve and promote apoptosis-related protein gene expression in brain glioblastoma cell or its stem cell;
9) prevent and/or treat glioma.
3rd purpose of the invention, which is to provide, a kind of has following 1) -9) product of at least one function.
Product provided by the invention, its active component are above-mentioned vinblastine liposome;
1) brain glioblastoma cell or its stem cell are killed;
2) brain glioblastoma cell or its stem cells hyperplasia are suppressed;
3) blood-brain barrier is crossed over;
4) brain glioblastoma cell or its stem cell apoptosis are promoted;
5) brain glioblastoma cell or the injury of mitochondria of its stem cell are promoted;
6) brain glioblastoma cell or its Stem Cell Activity oxygen level are improved;
7) brain glioblastoma cell or the micro-duct injury of its stem cell are promoted;
8) improve and promote apoptosis-related protein gene expression in brain glioblastoma cell or its stem cell;
9) prevent and/or treat glioma.
In above-mentioned, the rush apoptosis-related protein is caspase-3/7, caspase-8, caspase-9, Bax, cell color
Plain C, Mcl-1, LC3B or FoxO1;
Or the product is medicine or kit.
The experiment proves that the present invention has synthesized a kind of functionalization material TfR binding peptide-poly- second two
Alcohol-DSPE (TfR-T12-PEG2000- DSPE), and gather smart ammonia with itself and cationic materials stearyl eight
Acid (stearyl-R8) modification vinblastine liposome, blood-brain barrier can be crossed over and kill glioma and its do by obtaining one kind
The functionalization vinblastine liposome of cell.The functionalization vinblastine liposome has across blood-brain barrier and specific killing
Human brain glioma stem cells act on, and are a kind of new drug-loading systems, there is important academic significance and potential clinical value.
Brief description of the drawings
Fig. 1 is vinblastine structural formula schematic diagram.
Fig. 2 is synthetic product TfR-T12-PEG2000- DSPE MALDI-TOF-MS collection of illustrative plates.
Fig. 3 is functionalization vinblastine liposome structure schematic diagram.
Fig. 4 is the standard curve that HPLC methods determine vinblastine concentration-peak area.
Fig. 5 is the characteristic spectrum that HPLC methods determine vinblastine.
Fig. 6 is the test limit that HPLC methods determine vinblastine.
Fig. 7 is that functionalization vinblastine liposome AFM (AFM) observes result.
Fig. 8 is that functionalization vinblastine liposome transmission electron microscope (TEM) observes result.
Fig. 9 is vinblastine from the release rate in each group liposome.
Figure 10 is expression of the TfR in brain glioblastoma cell (A) and its stem cell (B).
Figure 11 is the expression feelings of cells and characteristic of stem mark TfR in brain glioblastoma cell and its stem cell
Condition.
Figure 12 is each preparation group to brain glioblastoma cell (A1) and its stem cell (A2) lethal effect
Figure 13 is expression of the TfR in brain microvessel endothelial cells in vitro (BMVECs).
Figure 14 is that each preparation group is crossed over after blood-brain barrier co-culture model to the lethal effect of brain glioblastoma cell.
Figure 15 is apoptosis induction effect of each preparation group to brain glioblastoma cell.
Figure 16 is apoptosis induction effect of each preparation group to human brain glioma stem cells.
Figure 17 is nucleus degree of impairment of each preparation group to brain glioblastoma cell.
Figure 18 is injury of mitochondria situation of each preparation group to brain glioblastoma cell.
Figure 19 is the facilitation that each preparation group discharges active oxygen to brain glioblastoma cell.
Figure 20 is Microtubule disruption situation of each preparation group to brain glioblastoma cell.
Figure 21 is activation of each preparation group to apoptosis enzyme caspase-3/7 in brain glioblastoma cell.
Figure 22 is activation of each preparation group to apoptosis enzyme caspase-8 in brain glioblastoma cell.
Figure 23 is activation of each preparation group to apoptosis enzyme caspase-9 in brain glioblastoma cell.
Figure 24 is expression facilitation of each preparation group to pro apoptotic protein Bax in brain glioblastoma cell.
Figure 25 be each preparation group to cytochrome c from the release facilitation in brain glioblastoma cell mitochondria.
Figure 26 is that each preparation group is acted on the expression inhibiting of anti-apoptotic proteins Mcl-1 in brain glioblastoma cell.
Figure 27 is that up-regulation of each preparation group to autophagy proteins LC3B in brain glioblastoma cell acts on.
Figure 28 is that up-regulation of each preparation group to autophagy proteins FoxO1 in brain glioblastoma cell acts on.
Figure 29 is normal nude mice brain tissue slice.
Figure 30 is lotus glioma nude mice brain tissue slice.
Figure 31 is real-time living imaging of the medicine in lotus glioma nude mice.
Figure 32 is in vitro imaging of the medicine in each organ of lotus glioma nude mice after administration 48h.
Figure 33 is lotus glioma nude mice Kapp Lan-Mei Ye survivorship curves after treatment.
Figure 34 is anti-human brain glioma stem cells effect of the medicine in lotus glioma nude mice.
Figure 35 is each organ hematoxylin-eosin (HE) dyeing of lotus glioma nude mice.
Embodiment
Experimental method used in following embodiments is conventional method unless otherwise specified.
Material used, reagent etc., unless otherwise specified, are commercially obtained in following embodiments.
Portion of material and instrument used are as follows in following embodiments 1:
NHS-PEG2000-DSPE(N-hydroxysuccinimidyl-polyethylene glycol distearoyl
Phosphatidyl ethanolamine) NOF Corp (Japanese NOF companies) is purchased from, Japan;TfR-T12(Thr-
His-Arg-Pro-Pro-Met-Trp-Ser-Pro-Val-Trp-Pro Hefei Guo Tai bio tech ltd) is purchased from, in
State;stearyl-R8(stearyl-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-NH2) limited purchased from Shanghai gill biochemistry
Company, China;Lecithin (egg yolk phosphatidylcholine, EPC), (Japanese NOF is public for NOF Corp
Department), Japan;Cholesterol (cholesterol), Haidian District, Beijing City microbiological culture media products factory (train by Beijing bispin microorganism
Support based articles factory), China;PEG2000-DSPE (polyethylene glycol-
Distearoylphosphatidyl ethanolamine, DSPE-PEG2000), (Japanese NOF is public for NOF Corp
Department), Japan;Vinblastine Sulfate (vinblastine), Nanjing Duolun Chemical Co., Ltd., China;DMF
(dimethylformamide, DMF, super dry solvent), Beijing lark prestige company, China;Methanol (methanol, HPLC level), write from memory
Gram company, Germany;Acetonitrile (acetonitrile, HPLC level), Merck & Co., Inc., Germany;Hepes (4- hydroxyethyl piperazineethanesulfonic acids,
4- (2-hydroxyethyl) -1-piperazine ethanesulfonic acid), Shanghai life work bioengineering share is limited
Company, China;Hyclone (Fetal bovine serum, FBS), PAN biotechnologies company, Germany;Phosphate buffer
Pulvis (phosphate buffer saline, PBS), Beijing prosperity Bioisystech Co., Ltd of ancient cooking vessel state, China;Used in remaining
Reagent is the pure rank of analysis, and Beijing traditional Chinese medicines Reagent Company is Chinese.
Bag filter (molecular cut off 3000Da, 8000-14000Da), the prosperous great achievement bio tech ltd in Beijing, in
State;The a ten thousandth gram precision electronic balances of BT-25S ten, Sartorius companies, Germany;Six magnetic force heating/constant temperature of HJ-6 types
Agitator, Ke Xi Instrument Ltd. of Community of Jin Tan County city, China;MALDI TOFMS
(MALDI-TOF-MS, matrix-assisted desorption/ionization time of flight mass),
Shimadzu companies, Japan;RE52CS Rotary Evaporators, Shanghai Yarong Biochemical Instrument Plant, China;SB-5200 ultrasonic machines, Ningbo
Xin Zhi bio tech ltd instrument, China;JY92-IID type ultrasonic cell disruptors, the new sesame biotechnology in Ningbo are limited
Company, China;ZWY-103B constant temperature culture oscillators, Shanghai ZHICHENG Anaiytical Instrument Manufacturing Co., Ltd., China;Tecnar G2
20ST types transmission electron microscope (transmission electron microscope, TEM), FEI Co., the U.S.;Laser
Scatter particle size determination instrument (Malvern Zetasizer 3000HS), Malvern instruments companies, Britain;
SPI3800N series SPA-400 types AFMs (AFM), NSK Co., Ltds, Japan;Shimadzu chromatograph (LC-
10AT), Shimadzu (Shimadzu) Co., Ltd, Japan;Reverse-phase chromatographic column (C18column, 5 μm, 250x4.6mm), Tuo Lunsi
Phenomenex companies, the U.S..
All data are represented with Mean ± SD.Using one-way analysis of variance (ANOVA), then by Bonferroni schools
Test, P<0.05 thinks there is significant difference.
Portion of material and instrument used are as follows in following embodiments 2:
Glioma U87-MG cell lines are purchased from Tumour Inst., Chinese Medical Academy;Serum-free replenishers,
Gibco companies, the U.S.;LIF ELISA (LIF) is purchased from Wuxi Yao Kemei bio tech ltd, China;Tire ox blood
Clearly, PAN companies, Germany;MEM, DMEM-F12 culture medium, insulin, EGF (EGF), basic fibroblast life
The long factor (bFGF), nonessential amino acid, pancreatin are purchased from Beijing Mai Chen Science and Technology Ltd.s, China;Anti-Human
Transferrin Receptor (CD71) antibody-FITC, Sino Biological Inc., China;
Anti-Human Nestin antibody-FITC, R&D companies, the U.S.;Anti-Human ABCG2(CD338)antibody-
FITC, Anti-Human CXCR4antibody-PE, and corresponding Isotype antibody are purchased from Biolegend companies, the U.S.;Phosphorus
Phthalate buffer (PBS), purchased from Beijing Ding Guo Bioisystech Co., Ltd;Sulforhodamine B (SRB) is purchased from Sigma companies, beautiful
State;Triton X-100 are purchased from Beijing Bioisystech Co., Ltd of Zhong Shan Golden Bridge (ZSGB-BIO), China;4% paraformaldehyde is purchased
From Mai Chen Science and Technology Ltd.s, China;Trichloroacetic acid (TCA) is purchased from Beijing Xing Jin chemical plant, China;Disposable cell culture
Experimental article (including Tissue Culture Plate blake bottle, culture dish, sterile centrifugation tube etc.) is purchased from healthy and free from worry (Corning) company, the U.S..
Cell culture incubator, Thermo companies, the U.S.;AirTECH cell super-clean benches, the safe and sound companies of Su Jing, China;TDZ4-WS low speed platforms
Formula centrifuge, Xiang Yi centrifuges Instrument Ltd., China;Tecan infinite F50 ELIASAs, Tecan companies, Switzerland;
TS-8 oscillator plates, its woods Bel's instrument manufacturing Co., Ltd of Haimen City, China;Inverted microscope, Chongqing optics electricity instrument
Device company, China;DK-S24 electric-heated thermostatic water baths, the upper grand experimental facilities Co., Ltd of Nereid, China;Flow cytometer (BD
FACS Calibur), Becton Dickinson companies, the U.S..
The portion of material and instrument of following embodiments 3 are as follows:
Glioma U87-MG cell lines are purchased from Tumour Inst., Chinese Medical Academy;Mouse brain capillary endothelial cell
(brain microvascular endothelial cells, BMVECs), purchased from clinical research institute of China-Japan Friendship Hospital;It is double
Anti- (penicillin, streptomysin) is purchased from Beijing Suo Laibao Science and Technology Ltd, China;Hyclone, PAN companies, Germany;MEM、
DMEM culture mediums, heparin, endothelial growth factor (ECGF), nonessential amino acid, pancreatin are limited purchased from Beijing morning science and technology advanced in years
Company, China;Anti-Mouse Transferrin Receptor (CD71) antibody-FITC, eBioscience companies,
The U.S.;Phosphate buffer (PBS), purchased from Beijing Ding Guo Bioisystech Co., Ltd;Sulforhodamine B (SRB) is purchased from Sigma
Company, the U.S.;Gelatin is purchased from Beijing Baeyer enlightening biotech company;Trichloroacetic acid (TCA) is purchased from Beijing Xing Jin chemical plant, in
State;Disposable cell culture experiments articles for use (including Tissue Culture Plate, Transwell polyester films inserter, blake bottle, culture dish,
Sterile centrifugation tube etc.) it is purchased from healthy and free from worry (Corning) company, the U.S..
The a ten thousandth gram precision electronic balances of BT-25S ten, Sartorius companies, Germany;Cell culture incubator, Thermo are public
Department, the U.S.;AirTECH cell super-clean benches, the safe and sound companies of Su Jing, China;TDZ4-WS low speed desk centrifuges, Hunan instrument centrifuge
Instrument Ltd., China;Tecan infinite F50 ELIASAs, Tecan companies, Switzerland;TS-8 oscillator plates, Haimen
Its woods Bel's instrument manufacturing Co., Ltd of city, China;ERS-2 cell resistance instrument, Millipore companies, the U.S..
The portion of material and instrument of following embodiments 4 are as follows:
Glioma U87-MG cell lines are purchased from Tumour Inst., Chinese Medical Academy;Human brain glioma stem cells GSCs is
This research is voluntarily obtained by Fiber differentiation;Serum-free replenishers, Gibco companies, the U.S.;LIF ELISA (LIF) is purchased
From Wuxi Yao Kemei bio tech ltd, China;Hyclone, PAN companies, Germany;Lowlenthal serum is purchased from Zhejiang day Hangzhoupro
Biotech inc, China;MEM, DMEM, DMEM-F12 culture medium, insulin, EGF (EGF), alkali
Property fibroblast growth factor (bFGF), nonessential amino acid, pancreatin (being free of EDTA) step the morning limited public affairs of science and technology purchased from Beijing
Department, China;Mitochondria red fluorescence probe (Mitotracker Deep Red FM), Hoechst 33342 are purchased from
Invitrogen companies, the U.S.;Micro-pipe red fluorescence probe (Tubulin-Tracker Red) is purchased from the green skies in Beijing
(Beyotime) company, China;Apoptosis kit (7-AAD and Annexin V-KeyFluor 647) is purchased from the triumphant base in Shanghai
Biological (KeyGEN Biotech), China;Active oxygen detection kit (DCFH-DA) is purchased from Beijing Puli's Lay (APPLYGEN),
China;anti-caspase 3/7antibody、anti-caspase 8antibody、anti-caspase 9antibody、
anti-Bax antibody、anti-cytochrome c antibody、anti-MCL-1antibody、anti-Forkhead
Box protein O1 (FoxO1), antibody and anti-LC3B antibody are purchased from the green skies in Beijing (Beyotime)
Company, China;Alexa488-conjugated goat anti-rabbit antibody、Alexa
488-conjugated goat anti-mouse antibody, Triton X-100 are purchased from Beijing Zhong Shan Golden Bridge biotechnology
Company (ZSGB-BIO), China;4% paraformaldehyde, which is purchased from, steps morning scientific and technological (Beijing) Co., Ltd, China;Glycine is purchased from traditional Chinese medicines
Group's chemical reagent Beijing Co., Ltd, China;Phosphate buffer (PBS), purchased from Beijing Ding Guo Bioisystech Co., Ltd;
Disposable cell culture experiments articles for use (including Tissue Culture Plate, blake bottle, sterile centrifugation tube, etc.) be purchased from healthy and free from worry (Corning)
Company, the U.S..The a ten thousandth gram precision electronic balances of BT-25S ten, Sartorius companies, Germany;Cell culture incubator, Thermo
Company, the U.S.;AirTECH cell super-clean benches, the safe and sound companies of Su Jing, China;TDZ4-WS low speed desk centrifuges, the centrifugation of Hunan instrument
Machine Instrument Ltd., China;Inverted microscope, Chongqing optics electro-kinetic instrument company, China;LEICA TCS-SP8 laser is total to
Focusing microscope (Confocal laser scanning fluorescent microscope), LEICA companies, Germany;Stream
Formula cell instrument (BD FACS Calibur), Becton Dickinson companies, the U.S.;The high intension analysis systems of Operetta,
Perkin Elmer companies, the U.S..
The portion of material and instrument of following embodiments 5 are as follows:
BALB/c male nude mouses (18-20g) are purchased from Peking University's Experimental Animal Center, China;Glioma U87-MG is thin
Born of the same parents' strain is purchased from Tumour Inst., Chinese Medical Academy;Hyclone, PAN companies, Germany;MEM culture mediums, non-essential amino
Acid, pancreatin are purchased from Beijing Mai Chen Science and Technology Ltd.s, China;Lowlenthal serum is purchased from the limited public affairs of Zhejiang day Hangzhoupro biotechnology share
Department, China;Hoechst 33342 is purchased from Invitrogen companies, the U.S.;Disposable syringe (1mL, 2mL and 5mL) is purchased from
Becton Dickinson (BD) company, the U.S.;DiR fluorescent dyes, purchased from Sigma companies, the U.S.;anti-nestin
Antibody is purchased from AbCam companies, Britain;Alexa488-conjugated goat anti-rabbit
Antibody, Triton X-100 are purchased from Beijing biotech company of Zhong Shan Golden Bridge (ZSGB-BIO), China;4% paraformaldehyde
Purchased from morning advanced in years scientific and technological (Beijing) Co., Ltd, China;Phosphate buffer (PBS), purchased from the limited public affairs of Beijing ancient cooking vessel state biotechnology
Department;Disposable cell culture experiments articles for use (including Tissue Culture Plate, blake bottle, sterile centrifugation tube, etc.) purchased from healthy and free from worry
(Corning) company, the U.S..
The a ten thousandth gram precision electronic balances of BT-25S ten, Sartorius companies, Germany;Cell culture incubator, Thermo are public
Department, the U.S.;AirTECH cell super-clean benches, the safe and sound companies of Su Jing, China;TDZ4-WS low speed desk centrifuges, Hunan instrument centrifuge
Instrument Ltd., China;Inverted microscope, Chongqing optics electro-kinetic instrument company, China;LEICA TCS-SP8 laser is copolymerized
Focusing microscope (Confocal laser scanning fluorescent microscope), LEICA companies, Germany;Brain is stood
Body position indicator, Shenzhen Rui Wode Life Sciences Co., Ltd, China;Caikon XDS-300C systems, Shanghai Cai Kang optical instruments
Co., Ltd, China;IVIS Spectrum living imaging systems, Perkin Elmer companies, the U.S..
All data are represented with Mean ± SD.Using one-way analysis of variance (ANOVA), then by Bonferroni schools
Test, P<0.05 thinks there is significant difference.Survival rate data are shown with kaplan-Meier survival curve, and are examined with log-rank
Test and do statistical procedures, P<0.05 thinks there is significant difference.
The structure and sign of embodiment 1, functionalization vinblastine liposome
First, the structure of functionalization vinblastine liposome
1、TfR-T12-PEG2000- DSPE synthesis
TfR-T12-PEG2000- DSPE is under the conditions of existing for catalyst, by TfR-T12Polypeptide and NHS-PEG2000-
DSPE carries out acylation reaction and obtained;Wherein TfR-T12Polypeptide and NHS-PEG2000- DSPE molar ratio is 1:1.
Specific synthetic method is as follows:
8 μm of ol TfR-T are added into reaction bulb12Polypeptide (THRPPMWSPVWP) and 8 μm of ol NHS-PEG2000- DSPE,
Dissolved with 2mL DMF, and add 200 μ L catalyst ns-methyl morpholine.It is transferred under normal temperature after stirring reaction 48h in bag filter
(molecular cut off 3000Da), it is placed in deionized water and dialyses 24 hours, removes solvent and unreacting material.It is afterwards that sample is cold
It is lyophilized dry, it is placed in -20 DEG C of preservations.
Product is verified using MALDI TOFMS (MALDI-TOF-MS), uses 2,5- bis-
Hydroxybenzoic acid (DHB) is as detection matrix.
As a result as shown in Fig. 2 the MALDI-TOF-MS collection of illustrative plates of product, the average molecular mass that product is shown in figure is
4441.77Da with reactant PEG2000Difference between-DSPE molecular weight (3000.00Da) is 1441.77Da, this and TfR-
T12Molecular weight (1490.80Da) coincide, illustrate target product TfR-T12-PEG2000- DSPE is synthesized successfully.
2nd, the preparation of functionalization vinblastine liposome
1) common vinblastine liposome
In molar ratio 60:30:3 precisions weigh lecithin (EPC), cholesterol (CHOL), PEG2000- DSPE is in eggplant-shape bottle
In, by volume 3:1 adds dichloromethane and methanol, has been removed under reduced pressure with Rotary Evaporators under 40 DEG C of water-baths, 90rpm rotating speeds
Solvent, obtain one layer of uniform film and be affixed on eggplant-shape bottle bottom.Add 50mL ammonium sulfate (250mM) aqueous solution and carry out aquation:First
Water bath sonicator 5min, completely falls off to film, and system is in the thick liposome of uniform milky;Thick liposome is shifted afterwards
Into EP pipes, with JY92-IID type ultrasonic cell disruptors further ultrasonic 10min (the setting ultrasound works time is 1s,
Intermittent time is 1s, and protection temperature is 30 DEG C, power 200W).After ultrasound terminates, obtain with the translucent of faint blue-opalescent
Liquid, the liquid is extruded and by the poly- carbon ester film that aperture is 200nm, obtained liquid is transferred in bag filter (retention point
Son amount 8000-14000Da), the dialysis 24h in HBS cushioning liquid (151mM NaCl, 25.2mM Hepes, pH 7.4), per 6h
Change liquid once.After dialysis terminates, blank liposomes liquid solution is obtained.
By medicine fat mass ratio 1:20 (w/w) precision weighing vinblastines are added in 25mL eggplant-shape bottles, are added methanol dissolving, are used
Methanol is removed under reduced pressure under 40 DEG C of water-baths, 90rpm rotating speeds in Rotary Evaporators, obtains dispersed vinblastine.Utilize sulfuric acid
Ammonium gradient carries medicine method, and the blank liposomes liquid solution of above-mentioned acquisition is added in the eggplant-shape bottle, 20min is shaken in 60 DEG C of water-baths,
Obtain common vinblastine liposome.
2)TfR-T12The vinblastine liposome of modification
It is identical with common vinblastine method for preparing lipidosome, but by PEG in film forming procedure2000- DSPE replaces with above-mentioned
1) TfR-T prepared12-PEG2000- DSPE, obtain TfR-T12The vinblastine liposome of modification.
3)Stearyl-R8The vinblastine liposome of modification
It is identical with common vinblastine method for preparing lipidosome, but in molar ratio 60 in film forming procedure:30:3:5 accurate titles
Take lecithin (EPC), cholesterol (CHOL), PEG2000-DSPE、stearyl-R8In eggplant-shape bottle, Stearyl-R is obtained8Modification
Vinblastine liposome.
4) functionalization vinblastine liposome
It is identical with common vinblastine method for preparing lipidosome, but in molar ratio 60 in film forming procedure:30:3:5 accurate titles
Take lecithin (EPC), cholesterol (CHOL), TfR-T12-PEG2000-DSPE、stearyl-R8In eggplant-shape bottle, functionalization is obtained
Vinblastine liposome.
Fig. 3 is the schematic diagram of functionalization vinblastine liposome, and lecithin constitutes the bilayer of liposome, has stream
Dynamic property, while insert the rigidity of cholesterol increase liposome.Functionalization material TfR-T12-PEG2000- DSPE and stearyl-R8
Modification actively enters the interior aqueous phase of liposome in surface of liposome, water-soluble vinblastine under ammonium sulphate gradient effect.
2nd, characterize
1st, vinblastine content assaying method
1) chromatographic condition
Chromatographic column:Luna C18 posts (Phenomenex, C18column, 5 μm, 250x4.6mm);Mobile phase:Methanol-
0.02M sodium dihydrogen phosphates (70:30, v/v);Detection wavelength:267nm;Flow velocity:1.0mL/min;Sample size:20 μ L, measure
Temperature:25℃.
2) standard curve
Precision weighing vinblastine, add proper amount of methanol dissolve and be diluted to concentration be respectively 0.78,1.56,3.12,
6.25th, 12.50,25.00,50.00,100.00 μ g/mL standard liquid.According to the chromatogram of above-mentioned chromatographic condition measure each sample
Peak area A values.Using vinblastine concentration C as independent variable, linear regression is carried out to its corresponding chromatographic peak area A value, tries to achieve length
The standard curve (Fig. 4) of spring flower alkali.Standard curve is y=19476x+1348.2, R2=1.
Vinblastine such as Fig. 5 of the chromatogram under this liquid-phase condition, its retention time are good in 7min or so, peak shape.3)
Return
Yield
Appropriate blank liposome is taken, the methanol for adding nonuploid product is destroyed.Then accurately weighed catharanthus roseus is added
Alkali reference substance is appropriate, adds flowing phased soln, is formulated as the solution of the μ g/mL containing vinblastine 12.50,25.00,50.00, mistake successively
Filter, peak area is determined with above-mentioned chromatographic condition respectively, calculate the rate of recovery.
As a result as shown in table 1, display, the rate of recovery is in the range of 96.49%-98.56%.
Table 1 is that HPLC-UV is determined in liposome to the rate of recovery of vinblastine
Notes:Data are presented as mean ± standard deviation (SD, n=5)
4) precision
Appropriate blank liposome is taken, the methanol for adding nonuploid product destroys.Then accurately weighed vinblastine pair is added
It is appropriate according to product, add flowing phased soln, the solution of the μ g/mL containing vinblastine 12.50,25.00,50.00 is formulated as successively, on 5th
Peak area inside is determined with above-mentioned chromatographic condition respectively, calculates in a few days and in the daytime relative standard deviation.
As a result as shown in Table 2, the in a few days and in the daytime relative deviation RSD of the method measure vinblastine<2%, the measure side
Method precision is good.
Table 2 is the measure of HPLC-UV method precisions
Notes:Data are presented as mean ± standard deviation (SD, n=5)
5) test limit
It is appropriate that precision weighs vinblastine reference substance, adds methanol to dissolve and dilute, it is molten to prepare standard successively by doubling dilution
Liquid, according to the chromatographic peak area of above-mentioned chromatographic condition determination sample.When signal to noise ratio is about 3:Detectable concentration when 1 is this method
Minimum detection limit.
As a result such as Fig. 6 is shown, the detection of this method measure vinblastine is limited to 0.024 μ g/mL.
2nd, the measure of envelop rate
The μ L of functionalization blank liposome 500 are taken by Sephadex G-50 sephadex columns, with HBS cushioning liquid
(25mM HEPES, 150mM NaCl, pH 7.4) is mobile phase presaturation sephadex column.Take drug-loaded liposome (general afterwards
Logical vinblastine liposome, TfR-T12Vinblastine liposome, the stearyl-R of modification8Vinblastine liposome, the work(of modification
Vinblastine liposome can be changed) 500 μ L are by Sephadex G-50 sephadex columns, using HBS cushioning liquid as mobile phase point
From the free vinblastine not wrapped into liposome, the liposome after separation is collected, nonuploid product methanol is added and destroys, and with flowing
After phase dilution, it is measured with above-mentioned high performance liquid chromatography.The liposome stoste for not crossing gel column is taken, adds nonuploid product first
Alcohol destroys, and with after the identical multiple of flowing phase dilution, is measured with above-mentioned high performance liquid chromatography.
The envelop rate of vinblastine in each liposome is calculated using equation below:
Envelop rate %=crosses amount × 100% of the amount of gel column liposome drug containing/do not cross gel column liposome drug containing.
Drug concentration Standard reference (comparing one point method) calculates, and produces.
Envelop rate of the vinblastine in each group liposome is all higher than 97.0%, is shown in Table 3.
Table 3 is the physicochemical characterization of liposome
Notes:Data are presented as mean ± standard deviation (SD, n=3)
3rd, the measure of particle diameter and Zeta potential
1) measure of particle diameter
Common vinblastine liposome, TfR-T are taken respectively12Vinblastine liposome, the stearyl-R of modification8Modification
Vinblastine liposome, functionalization vinblastine liposome, 20 times are diluted with PBS, takes 1mL to add sample cell, is dissipated using laser
The particle diameter (angle of wavelength 633nm, incident light and scattered beam is 90 °) of radion footpath analyzer measure liposome, each sample
Equilibration time is 120s, determines 20 circulation times, and measurement temperature is set as 25 DEG C.The last measurement result of each sample is 20
The average value of secondary measurement result.The uniformity coefficient of polydispersity expression particle size, the smaller then particle of polydispersity are more uniform.
As a result as shown in table 3, the average grain diameter of each liposome in the range of 90-120nm, polydispersity coefficient (PDI,
Polydisperisty indexes) between 0.176-0.253.
2) measure of Zeta potential
After having determined particle diameter, by common vinblastine liposome, TfR-T12Vinblastine liposome, the stearyl- of modification
R8Vinblastine liposome, the functionalization vinblastine liposome of modification are transferred in current potential cup that (solution will flood conductive copper
Piece), it is equilibration time 120s to set Zeta potential condition determination, and at least 20 circulation times of measure, measurement temperature are set every time
For 25 DEG C.The last measurement result of each sample is the average value of 20 measurement results.
As a result as shown in table 3, stearyl-R8The liposome Zeta potential of modification is just, other groups of liposomes shows slightly negative
Electricity.
4th, morphological observation
1) AFM (AFM) is observed
Using deionized water as decentralized medium, by unmodified common vinblastine liposome and functionalization catharanthus roseus
Alkali liposome is diluted to 100 μ g/mL (fat material concentration) and with 0.2 μm of filtering with microporous membrane.10 μ L dilutions are taken to be applied to silicon chip table
Face, it is stored at room temperature after drying, is detected and recorded with AFM tapping-mode.
As a result as shown in fig. 7, A1 is common vinblastine liposome, A2 is functionalization vinblastine liposome, atomic force
Under microscope, two kinds of liposomes are rendered as surface rounding, smooth form, particle diameter 100nm or so, with particle size results phase
Symbol.
2) transmission electron microscope (TEM) is observed
Using deionized water as decentralized medium, by unmodified common vinblastine liposome and functionalization catharanthus roseus
Alkali liposome is diluted to 1 μ g/mL (fat material concentration) and with 0.2 μm of filtering with microporous membrane.Then, the copper mesh for being covered with carbon film is placed on
On liposome solutions, taken out after 1min, after being blotted with filter paper, it is double that the copper mesh drift that capture there are liposome particles is placed on 1% acetic acid
On the oxygen uranium aqueous solution, take out after 1min and blotted with filter paper.After left at room temperature over night dries, using transmission electron microscope instrument in 120kV
Under be observed and record.
As a result such as Fig. 8 shows that A1 is common vinblastine liposome, and A2 is functionalization vinblastine liposome, transmission electricity
Under mirror, two kinds of liposomes are rendered as the spherical of the smooth of the edge rounding, particle diameter 100nm or so, are consistent with particle size results.
5th, drug release rate
Extracorporeal releasing experiment is carried out in the dissolution medium (PBS for containing 10% hyclone) containing haemocyanin.
The common vinblastine liposomes of 1mL, TfR-T are taken respectively12Vinblastine liposome, the stearyl-R of modification8The catharanthus roseus of modification
Alkali liposome, functionalization vinblastine liposome add in bag filter (8000-14000Da), and add 1mL dissolution mediums, use
Suture is placed in after tightening in the cillin bottle equipped with 20mL dissolution mediums, is put into shaking table, starts to shake under the conditions of 37 DEG C, 100rpm
Swing.0.2mL dissolution mediums are taken out respectively at 1,2,4,8,12,24h, and fill into the new release of equal volume after every sub-sampling immediately
Medium.
Each part sample methanol (sample taken out:Methanol=2:8, v/v) destruction dilution is carried out, separates out albumen, at a high speed
Centrifugation, then film is crossed with filter membrane, high molecular weight protein is removed, peak area corresponding to vinblastine is measured in each sample with HPLC,
Calculate concentration using the equation of linear regression of gained, so as to calculate each sample in burst size at different moments, obtain its
The cumulative release amount at a certain moment.
Release in vitro rate is calculated with following formula:
Release in vitro rate %=(amount of medicine in the i-th time point release liquid/with dialysis volume identical dialysis proliposome
The amount of drug in solution) × 100%.
Each group liposome such as Fig. 9 of the releasing result in dissolution medium, as a result shows, length of each group liposome in 24h
Spring flower alkali release rate is below 12%.
The above results show that functionalization vinblastine liposome is by functionalization material TfR-T12-PEG2000- DSPE and
stearyl-R8Modify on liposome and wrapped into using ammonium sulphate gradient by vinblastine obtained by liposome.
Embodiment 2, functionalization vinblastine liposome are trained to glioma and its stem cell target lethal effect cell
Support
First, cell culture
Brain glioblastoma cell U87-MG cells are cultivated in the MEM culture mediums containing 10%FBS and 1% nonessential amino acid,
Condition of culture is 37 DEG C, containing 5%CO2。
The induction of human brain glioma stem cells (glioma stem cells, GSCs) and culture (Yu SC;Ping YF;Yi
L;Zhou ZH;Chen JH;Yao XH;Gao L;Wang JM;Bian XW.Isolation and characterization
of cancer stem cells from a human glioblastoma cell line U87[J].Cancer
Letters,2008,265(1):124-34):With every mL 2 × 104The concentration of individual U87-MG cells is containing 2%Serum-free
Replenishers, 10ng/mL LIF, 20ng/mL EGF, 20ng/mL bFGF, the DMEM-F12 culture mediums of 181.6ng/mL insulin
The middle culture that suspends, condition of culture is 37 DEG C, containing 5%CO2.Identified after culture four weeks.
Mouse brain capillary endothelial cell BMVECs containing 20%FBS, 100U/mL penicillin, 100 μ g/mL streptomysins,
40U/mL heparin, 100ug/mL ECGF DMEM culture mediums in cultivate, condition of culture be 37 DEG C, containing 5%CO2.Blake bottle shifts to an earlier date
30min is handled with 2% gelatin solution.The compound method of 2% gelatin solution:2g gelatin is weighed, with 100ml Hank ' s solution (80
DEG C) scattered, swelling, filtration sterilization, 4 DEG C of preservations.
2nd, glioma and its stem cell TfR mark
BSA buffer solutions:500mg BSA and 74.45mg EDTA are added in per 100mL PBSs.
Respectively collect GSCs (B), U87-MG cells (A), add BSA buffer solutions cell is resuspended, by cell dispense to
In 1.5mL EP pipes, 1 × 10 is often added in pipe7Individual cell.5 μ L Anti- are added into GSCs and U87-MG experimental group
Human Transferrin Receptor (CD71) antibody-FITC, while add 5 μ L Isotype controls into control group and resist
Body, it is incubated at room temperature 20min.Cell is washed twice with PBS afterwards, is resuspended with 300 μ L PBS and is crossed 400 mesh sieves into streaming pipe, on
Lucifuge ice bath preserves before machine.
Determined using flow cytometer FACScan flow cytometer, come using forward angle light scatter and side scatter
Exclude double cell masses.The excitation wavelength for detecting FITC is 488nm, launch wavelength 530nm.
As a result such as Figure 10 is shown, expression feelings of the TfR in brain glioblastoma cell (A) and its stem cell (B)
Condition, showing, TfR has expression on two kinds of cells, wherein, the expression quantity in U87-MG is 94.65% (A).
3rd, the identification of human brain glioma stem cells
Human brain glioma stem cells GSCs is induced and characteristic indication thing is identified after cultivating four weeks, including nestin
(nestin)、ABCG2、CXCR4.Equivalent U87-MG cells are taken to be compareed simultaneously.
The cell ball for the culture that suspends is centrifuged, is single cell suspension with the digestion of 0.05% pancreatin, dispenses to 1.5mL EP and manage
It is interior, 1 × 10 is often added in pipe7Individual cell.
For nestin mark:With the paraformaldehyde of 4% ice in 4 DEG C of fixed 10min, then with 0.2%Triton X-
100 solution are incubated 10min to Cell-transmission model at room temperature, and 10 μ L Anti- are added into the experimental group of GSCs and U87-MG cells
Human Nestin antibody-FITC, while 10 μ L isotype control Abs are added into control group, fully piping and druming mixes, room
The lower lucifuge of temperature is incubated 30min.Cell is washed twice with PBS afterwards, is resuspended with 300 μ L PBS and is crossed 400 mesh sieves into streaming pipe, on
Lucifuge ice bath preserves before machine.
For ABCG2 mark:With the paraformaldehyde of 4% ice in 4 DEG C of fixed 10min, to GSCs and U87-MG cells
Experimental group in add 5 μ L Anti-Human ABCG2 (CD338) antibody-FITC, while 5 μ L are added into control group
Isotype control Ab, fully piping and druming mix, and lucifuge is incubated 30min at room temperature.Cell is washed twice with PBS afterwards, with 300 μ L PBS
It is resuspended and crosses 400 mesh sieves into streaming pipe, lucifuge ice bath preserves before upper machine.
For CXCR4 mark:Use Anti-Human CXCR4 antibody-PE and corresponding Isotype antibody, step
Same ABCG2.
Determined using flow cytometer FACScan flow cytometer, come using forward angle light scatter and side scatter
Exclude double cell masses.The excitation wavelength for detecting FITC is 488nm, launch wavelength 530nm;Detection FITC excitation wavelength be
488nm, launch wavelength 564nm.
As a result as shown in figure 11, ABCG2 is in brain glioblastoma cell (A1) and its stem cell (A2) in expression;CXCR4 is in brain
Glioma cell (B1) and its stem cell (B2) in expression;Nestin is in brain glioblastoma cell (C1) and its stem cell (C2) in
Expression;Figure 11 B1With Figure 11 B2It has been shown that, expression quantity of the ABCG2 in U87-MG and GSCs is respectively 5.76% and 23.93%;
Figure 11 B1With Figure 11 B2It has been shown that, expression quantity of the CXCR4 in U87-MG and GSCs is respectively 22.80% and 98.60%;Figure 11 C1
With Figure 11 C2It has been shown that, expression quantity of the nestin in U87-MG and GSCs is respectively 39.36% and 97.77%.As a result show, three
Expression of the kind characteristic indication thing in GSCs increases than U87-MG, shows to induce stem cell success.
4th, to brain glioblastoma cell and its lethal effect of stem cell
1. cell is inoculated with
U87-MG the and GSCs cells of digestion exponential phase are collected, respectively with each hole 4 × 103(180 μ L are trained individual cell
Support base) it is inoculated on 96 orifice plates, if six multiple holes, at 37 DEG C, containing 5%CO2Incubator in be incubated 24h.
2. dosage regimen
Free vinblastine, common vinblastine liposome, the TfR-T of series concentration are prepared with serum free medium12Repair
Vinblastine liposome, the stearyl-R of decorations8Vinblastine liposome, the functionalization vinblastine liposome of modification.Add per hole
Enter 20 μ L, make final concentration of 0-50 μM of vinblastine.96 well culture plates after dosing, it is placed in 37 DEG C, containing 5%CO2Culture
It is incubated in case, continues to be incubated 48h.
3. measure and calculating
After incubation terminates, 96 well culture plates are taken out, discard culture medium, the trichloroacetic acid (TCA) 200 of 10% ice is added per hole
μ L, placed under the conditions of 4 DEG C and fix cell more than 1h.Then with 5 times culture plates of water washing are distilled, to remove trichloroacetic acid.
After being dried overnight in air, to every μ L 0.4% of Kong Zhongjia 100 SRB (being prepared with 1% glacial acetic acid), 15min is placed at room temperature
After discard liquid, washed 5 times with 1% acetic acid, to remove uncombined dyestuff, 200 μ L added per hole after air drying
10mmol/L Tris base (pH 10.5) dissolve, and vibrate 30min on oscillator plate (decolorization swinging table), whole to dyestuff
Dissolving.Put in ELIASA and determined under 540nm wavelength per hole OD value (OD).Using after the dosing culture cell deposit
Percentage (Cell survival rate, %) live to evaluate the toxic action of each preparation on cells.Cell survival percentage is pressed
Calculated according to equation below:
As a result as shown in figure 12, one group of block diagram under each concentration is followed successively by:Free vinblastine, vinblastine lipid
Body, TfR-T12The vinblastine liposome of modification, stearyl-R8The vinblastine liposome of modification, functionalization vinblastine fat
Plastid, functionalization blank liposome;Figure 12 A1 and Figure 12 A2Represent each preparation group to external U87-MG and GSCs cells respectively
Depression effect.As a result show, functionalization vinblastine liposome has most strong Proliferation Ability to make for U87-MG and GSCs
With.Proliferation Ability ability sequence consensus of each preparation group to U87-MG and GSCs:Functionalization vinblastine liposome>stearyl-
R8The vinblastine liposome of modification>TfR-T12The vinblastine liposome of modification>Common vinblastine liposome>Free Changchun
Flower alkali>Functionalization blank liposome.Functionalization vinblastine liposome suppresses U87-MG and GSCs cell proliferations.
Embodiment 3, functionalization vinblastine liposome are in the effect across blood-brain barrier
First, cell culture
Mouse brain capillary endothelial cell BMVECs containing 20%FBS, 100U/mL penicillin, 100 μ g/mL streptomysins,
40U/mL heparin, 100ug/mL ECGF DMEM culture mediums in cultivate, condition of culture be 37 DEG C, containing 5%CO2.Blake bottle shifts to an earlier date
30min is handled with 2% gelatin solution.The compound method of 2% gelatin solution:2g gelatin is weighed, with 100ml Hank ' s solution (80
DEG C) scattered, swelling, filtration sterilization, 4 DEG C of preservations.
2nd, BMVECs surfaces TfR marks
BSA buffer solutions:500mg BSA and 74.45mg EDTA are added in per 100mL PBSs.
BMVECs cells are collected, adding BSA buffer solutions is resuspended cell, and cell is dispensed into 1.5mL EP pipes, often managed
It is middle to add 1 × 107Individual cell.5 μ L Anti-Mouse Transferrin Receptor are added into BMVECs experimental group
(CD71) antibody-FITC, while 5 μ L isotype control Abs are added into control group, it is incubated at room temperature 20min.Cell afterwards
Washed twice with PBS, be resuspended with 300 μ L PBS and cross 400 mesh sieves into streaming pipe, lucifuge ice bath preserves before upper machine.
Determined using flow cytometer FACScan flow cytometer, come using forward angle light scatter and side scatter
Exclude double cell masses.The excitation wavelength for detecting FITC is 488nm, launch wavelength 530nm.
As a result if Figure 13, expression quantity of the TfR in BMVECs are 17.68%.
2nd, the foundation and evaluation of blood-brain barrier model
With the advance coated cell inserter 30min of 2% gelatin, by BMVECs with every hole 1 × 104The density of individual cell adds
Into the cell inserter being coated with (per hole 1mL culture mediums), and add in lower room the culture medium of 1mL U87-MG cells.Often
Change a subculture within two days, co-culture 6 days.
The close connection that BMVECs is formed is observed under the microscope, carries out preliminary assessment;It is thin using the detection of cell resistance instrument
Born of the same parents' inserter and the transepithelial electrical resistance (TEER) in lower room.It was found that the blood-brain barrier model TEER values established are all higher than 300
Ω·cm2.Therefore, in vitro blood-brain barrier model is successfully established.
3rd, the foundation of BMVECs/U87-MG co-culture models
With every hole 2 × 103Density add U87-MG cells (1mL culture mediums) in 12 orifice plates, and will before be covered with
BMVECs cell inserter is transferred to above 12 orifice plates, at 37 DEG C, containing 5%CO2Incubator in co-incubation 24h, produce
To BMVECs/U87-MG co-culture models.
4th, across killing glioma effect after blood-brain barrier
Each group preparation is separately added into the cell inserter of the BMVECs/U87-MG co-culture models of foundation, to prescription
Case is as follows:Free vinblastine, common vinblastine liposome, TfR-T12Vinblastine liposome, the stearyl-R of modification8
Vinblastine liposome, the functionalization vinblastine liposome of modification, to add the holes of blank cultures as blank control group,
Hole not to be covered with BMVECs is used as positive controls, the final concentration of 50nM of vinblastine.At 37 DEG C, containing 5%CO2Culture
After being incubated 48h in case, liquid is discarded, the trichloroacetic acids of 2mL 10% are added per hole, 1h is placed in 4 DEG C of refrigerators and fixes cell.Training
Support each hole of plate to be washed with deionized 5 times, to remove TCA.After drying in atmosphere, add 1mL 0.4%SRB per hole, at room temperature
15min is placed, discards in each hole and is washed 5 times with 1% glacial acetic acid-aqueous solution after liquid, uncombined dyestuff is removed, is done in air
It is dry after with pH 10.5,10mmol/L Tris alkali 2mL dissolving, 30min is vibrated on oscillator plate, put in ELIASA in
Determined under 540nm wavelength per hole trap OD values, calculate survival rate.Survival rate=(A540nmPreparation group/A540nmControl group) x
100%, A540nmIt is the absorbance under 540nm.
As a result as shown in figure 14,1, dissociate vinblastine;2, vinblastine liposome;3, TfR-T12The vinblastine of modification
Liposome;4, stearyl-R8The vinblastine liposome of modification;5, functionalization vinblastine liposome;Represent each preparation group across
More depression effect of the in vitro blood-brain barrier to external U87-MG cells.As a result show, functionalization vinblastine liposome has most
Strong has most strong inhibited proliferation across in vitro blood-brain barrier ability and for U87-MG.Each group survival rate order be:
Blank control group>Free vinblastine>Common vinblastine liposome>stearyl-R8The vinblastine liposome of modification>
TfR-T12The vinblastine liposome of modification>Functionalization vinblastine liposome>Positive controls.Wherein, in positive controls,
BMVECs is not laid in cell inserter, the false positive results that are likely to occur in experimentation are excluded with this.
The liposome-induced glioma apoptosis effect of embodiment 4, functionalization vinblastine
First, the liposome-induced glioma apoptosis effect of functionalization vinblastine
1. cell is inoculated with
By brain glioblastoma cell U87-MG and human brain glioma stem cells GSCs with every hole 5 × 105The density difference of individual cell
It is inoculated in 6 orifice plates, and adds 2mL culture mediums, at 37 DEG C, containing 5%CO2Incubator in be incubated 24h.
2. dosage regimen
Culture medium is discarded, is separately added into free vinblastine, common vinblastine fat that 2mL is prepared with serum free medium
Plastid, TfR-T12Vinblastine liposome, the stearyl-R of modification8Vinblastine liposome, the functionalization vinblastine of modification
Liposome solutions, it is 30nM to make vinblastine concentration;Blank group adds serum free medium, is placed in 37 DEG C, containing 5%CO2Training
Support and be incubated in case.After being incubated 12h, with PBS cell 2 times, cell dissociation is got off and centrifuged using the pancreatin without EDTA
Cell is collected, is scattered in 300 μ l Binding buffer and (is provided in kit), 400 mesh sieves is crossed into streaming pipe, adds
10 μ L Annexin V-KeyFluor 647, room temperature lucifuge are incubated 15min, and 5min adds 10 μ L7-AAD before upper machine.Use 2mM
Dioxygen water process cell 2h individually marks as positive control, and with Annexin V-kFluor647 and 7-AAD.
3. measure and calculating
Determined using flow cytometer FACScan flow cytometer, come using forward angle light scatter and side scatter
Exclude double cell masses.The excitation wavelength for detecting KeyFluor 647 is 651nm, launch wavelength 667nm;Detect 7-AAD's
Excitation wavelength is 546nm, launch wavelength 647nm.Rational cross door is being set using single standard specimen notebook data, and is carrying out data
Processing.
Apoptosis rate=experimental group apoptosis rate-blank group apoptosis rate
Apoptosis induction effect such as Figure 15 (a, blank control of the preparation to brain glioblastoma cell and its stem cell;B, length of dissociating
Spring flower alkali;C, vinblastine liposome;D, TfR-T12The vinblastine liposome of modification;E, stearyl-R8The catharanthus roseus of modification
Alkali liposome;F, functionalization vinblastine liposome) and Figure 16 (a, blank control;B, dissociate vinblastine;C, vinblastine fat
Plastid;D, TfR-T12The vinblastine liposome of modification;E, stearyl-R8The vinblastine liposome of modification;F, functionalization length
Spring flower alkali liposome) shown in.Cross door determines that each result has been divided into four parts by it according to feminine gender group and two single sun groups,
Lower-left (Lower Left, LL) represents normal cell, and bottom right (Lower Right, LR) represents apoptosis early stage cell, upper right
(Upper Right, UR) represents apoptosis late cell or non-viable non-apoptotic cell.
As a result show, functionalization vinblastine liposome is respectively provided with most strong apoptosis to brain glioblastoma cell and its stem cell
Inductive effect, and apoptosis early stage (being early apoptosis in cross door lower right area) is mainly reflected in, and apoptosis late period is without obvious
Change.
For brain glioblastoma cell, the order of each preparation induction early apoptosis is:Functionalization vinblastine liposome
(40.98%)>stearyl-R8The vinblastine liposome (28.90%) of modification>TfR-T12The vinblastine liposome of modification
(24.01%)>Free vinblastine (23.79%)>Vinblastine liposome (17.82%).
For human brain glioma stem cells, the order of each preparation induction early apoptosis is:Functionalization vinblastine liposome
(15.36%)>stearyl-R8The vinblastine liposome (10.90%) of modification>TfR-T12The vinblastine liposome of modification
(9.70%)>Free vinblastine (7.23%)>Vinblastine liposome (7.29%).
2nd, to the damage effect of brain glioblastoma cell core and mitochondria
By brain glioblastoma cell U87-MG with every hole 5 × 103It is thin that the density of individual cell (180uL culture mediums) is inoculated in 96 holes
In born of the same parents' culture plate, at 37 DEG C, containing 5%CO2Incubator in be incubated 24h.Free vinblastine, common is added into each group respectively
Vinblastine liposome, TfR-T12Vinblastine liposome, the stearyl-R of modification8The vinblastine liposome of modification, function
Change vinblastine liposome solutions, it is 30nM to make vinblastine concentration;Blank group adds serum free medium.Every group of preparation is set
6 multiple holes, in 37 DEG C, 5%CO2It is incubated in incubator.After 12h, culture medium is discarded, PBS is washed 2 times, and it is red to add mitochondria
Fluorescence probe (Mitotracker Deep Red FM, 200nM) and Hoechst 33342 (5 μ g/mL) are incubated at 37 DEG C
30min, then, add 200 μ L serum free mediums with PBS twice.
Picture is gathered to every hole under 10 times of eyepieces using Operetta High content screenings system and determines fluorescence intensity.
Picture is gathered to each group using Operetta high intensions, gathered picture is analyzed with Columbus system
The degree of variation of middle nucleus, and quantified.Cell nuclear damage ratio=experimental group nucleus Variation factor/blank group
Nucleus Variation factor.
As a result as Figure 17 (1, blank control;2, dissociate vinblastine;3, vinblastine liposome;4, TfR-T12Modification
Vinblastine liposome;5, stearyl-R8The vinblastine liposome of modification;6, functionalization vinblastine liposome.) shown in,
Cell nuclear damage ratio order be:Functionalization vinblastine liposome (1.64 ± 0.12)>stearyl-R8The catharanthus roseus of modification
Alkali liposome (1.43 ± 0.08)>TfR-T12The vinblastine liposome (1.44 ± 0.08) of modification>Vinblastine liposome
(1.21±0.09)>Free vinblastine (1.15 ± 0.05).
Picture is gathered to each group using Operetta high intensions, gathered picture is analyzed with Columbus system
The degree of variation of middle nucleus, and quantified.Injury of mitochondria ratio=experimental group mitochondria Variation factor/blank group
Mitochondria Variation factor.As a result as Figure 18 (1, blank control;2, dissociate vinblastine;3, vinblastine liposome;4,
TfR-T12The vinblastine liposome of modification;5, stearyl-R8The vinblastine liposome of modification;6, functionalization vinblastine
Liposome) shown in, injury of mitochondria ratio order is:Functionalization vinblastine liposome (1.281 ± 0.013)>stearyl-
R8The vinblastine liposome (1.226 ± 0.022) of modification>TfR-T12The vinblastine liposome (1.215 ± 0.023) of modification
>Free vinblastine (1.141 ± 0.027)>Vinblastine liposome (1.137 ± 0.035).
3rd, to the regulation and control of brain glioblastoma cell reactive oxygen species
By brain glioblastoma cell U87-MG with every hole 5 × 105The density of individual cell is inoculated in 6 orifice plates, 37 DEG C, contain
5%CO2Incubator in be incubated 24h.
Culture medium is discarded, is separately added into free vinblastine, common vinblastine fat that 2mL is prepared with serum free medium
Plastid, TfR-T12Vinblastine liposome, the stearyl-R of modification8Vinblastine liposome, the functionalization vinblastine of modification
Liposome solutions, it is 30nM to make vinblastine concentration;Blank group adds serum free medium, is placed in 37 DEG C, containing 5%CO2Training
Support and be incubated in case.After being incubated 12h, 500 μ L DCFH-DA (1 μM) are added into each hole, at 37 DEG C with PBS cell twice
After lower incubation 0.5h, cell is collected by centrifugation, cell is resuspended with 300 μ L PBS and crosses 400 mesh sieves into streaming pipe.
Determined using flow cytometer FACScan flow cytometer, come using forward angle light scatter and side scatter
Exclude double cell masses.The excitation wavelength of detection is 485nm, launch wavelength 525nm.
Each group cell be induced produce active oxygen horizontal result such as Figure 19 (1, blank control;2, dissociate vinblastine;3,
Vinblastine liposome;4, TfR-T12The vinblastine liposome of modification;5, stearyl-R8The vinblastine liposome of modification;
6, functionalization vinblastine liposome) shown in, each group reactive oxygen species order is:Functionalization vinblastine liposome>
stearyl-R8The vinblastine liposome of modification>TfR-T12The vinblastine liposome of modification>Vinblastine liposome>It is free
Vinblastine.
4th, to the damage effect of destruction brain glioblastoma cell micro-pipe
By brain glioblastoma cell U87-MG with every hole 2 × 105The density of individual cell is inoculated in Glass bottom culture dish, 37
DEG C, containing 5%CO2Incubator in be incubated 24h.
After 24h, culture medium is discarded, is separately added into free vinblastine, common Changchun that 1mL is prepared with serum free medium
Flower alkali liposome, TfR-T12Vinblastine liposome, the stearyl-R of modification8The vinblastine liposome of modification, functionalization length
Spring flower alkali liposome solutions, it is 30nM to make vinblastine concentration;Blank group adds serum free medium.It is placed in 37 DEG C, containing 5%
CO2Incubator in be incubated.After being incubated 3h, add micro-pipe red fluorescence probe (Tubulin- with PBS cell twice
Tracker Red) 0.5h is incubated, add Hoechst 33342 (5 μ g/mL) and be incubated 10min, then, add with PBS twice
Enter 1mL serum free mediums, IMAQ is carried out using laser confocal microscope.
Each preparation is as shown in figure 20 to the destruction result of micro-pipe in brain glioblastoma cell, a, blank control;B, Changchun of dissociating
Flower alkali;C, vinblastine liposome;D, TfR-T12The vinblastine liposome of modification;E, stearyl-R8The vinblastine of modification
Liposome;F, functionalization vinblastine liposome;In blank group (Figure 20 a), it may be observed that clearly thread tubulin, micro-pipe
Prop up whole cell and be in strip fusiform, be the representative configuration of glioma.And in functionalization vinblastine liposome group (figure
In 20f), it is impossible to which, it was observed that thread tubulin, whole cell also loses original shape and is rounded.Each preparation group is to brain glue
Microtubule disruption ability order is in matter oncocyte:Functionalization vinblastine liposome>stearyl-R8The vinblastine fat of modification
Plastid (Figure 20 e)>TfR-T12The vinblastine liposome (Figure 20 d) of modification>Vinblastine liposome (Figure 20 c)>Free Changchun
Flower alkali (Figure 20 b).
5th, the mechanism of brain glioblastoma cell apoptosis is induced
By brain glioblastoma cell U87-MG with every hole 5 × 103It is thin that the density of individual cell (180uL culture mediums) is inoculated in 96 holes
In born of the same parents' culture plate, at 37 DEG C, containing 5%CO2Incubator in be incubated 24h.Free vinblastine, common is added into each group respectively
Vinblastine liposome, TfR-T12Vinblastine liposome, the stearyl-R of modification8The vinblastine liposome of modification, function
Change vinblastine liposome solutions, it is 30nM to make vinblastine concentration;Blank group adds serum free medium.Every group of preparation is set
6 multiple holes, in 37 DEG C, 5%CO2It is incubated in incubator.After 6h, culture medium is discarded, PBS is washed 2 times, adds 4% paraformaldehyde
Fixed 15min, cold PBS are washed 2 times;Add the PBS punchings 15min containing 0.5%Triton X-100 and 0.3M glycine
Afterwards, 2h is closed using the PBS room temperatures containing 5% sheep blood serum.It is separately added into and dilutes corresponding times according to specification with antibody diluent
Several anti-caspase 3/7antibody, anti-caspase 8antibody, anti-caspase 9antibody,
anti-Bax antibody、anti-cytochrome c antibody、anti-MCL-1antibody、anti-Forkhead
Box protein O1 (FoxO1) antibody and anti-LC3B antibody, 4 DEG C of overnight incubations, then (are contained with PBST
0.05%Tween20 PBS solution) embathe 3 times, each 2min.Corresponding to adding afterwards488 secondary antibodies (1:
500 dilutions) room temperature lucifuge incubation 2h, is embathed 3 times, each 2min with PBS.Add (the 5 μ g/ of core dyestuff Hoechst 33342
Ml 10min) is incubated, is embathed 3 times with PBS, each 2min.Finally, mounting liquid (PBS for containing 90% glycerine) is added, 4 DEG C of lucifuges are protected
Deposit.
The fluorescence intensity in each hole is determined under 20 times of eyepieces using Operetta High content screenings system, is used in combination
Columbus system carry out data processing.
1. pro apoptotic protein caspase-3/7
Utilize pro apoptotic protein Caspase in the high intension measure each group cells of Operetta
(caspase-3/7) expression, with Columbus system calculate fluorescence intensity in each group.
Caspase-3/7 expresses multiple=experimental group fluorescence intensity/blank group fluorescence intensity.As a result display (Figure 21,1, blank control;
2, dissociate vinblastine;3, vinblastine liposome;4, TfR-T12The vinblastine liposome of modification;5, stearyl-R8Modification
Vinblastine liposome;6, functionalization vinblastine liposome), caspase-3/7 order of representation is:Functionalization vinblastine
Liposome (1.24 ± 0.05)>TfR-T12The vinblastine liposome (1.15 ± 0.02) of modification>stearyl-R8The length of modification
Spring flower alkali liposome (1.13 ± 0.03)>Free vinblastine (1.11 ± 0.01)>Vinblastine liposome (1.03 ± 0.02).
2. pro apoptotic protein caspase-8
Utilize pro apoptotic protein Caspase in the high intension measure each group cells of Operetta
(caspase-8) expression, with Columbus system calculate fluorescence intensity in each group.caspase-8
Express multiple=experimental group fluorescence intensity/blank group fluorescence intensity.As a result display (Figure 22,1, blank control;2, dissociate catharanthus roseus
Alkali;3, vinblastine liposome;4, TfR-T12The vinblastine liposome of modification;5, stearyl-R8The vinblastine fat of modification
Plastid;6, functionalization vinblastine liposome), caspase-8 order of representation is:Functionalization vinblastine liposome (1.28 ±
0.02)>TfR-T12The vinblastine liposome (1.24 ± 0.04) of modification>stearyl-R8The vinblastine liposome of modification
(1.22±0.02)>Vinblastine liposome (1.17 ± 0.02)>Free vinblastine (1.10 ± 0.05).
3. pro apoptotic protein caspase-9
Utilize pro apoptotic protein Caspase in the high intension measure each group cells of Operetta
(caspase-9) expression, with Columbus system calculate fluorescence intensity in each group.caspase-9
Express multiple=experimental group fluorescence intensity/blank group fluorescence intensity.As a result display (Figure 23,1, blank control;2, dissociate catharanthus roseus
Alkali;3, vinblastine liposome;4, TfR-T12The vinblastine liposome of modification;5, stearyl-R8The vinblastine fat of modification
Plastid;6, functionalization vinblastine liposome), caspase-9 order of representation is:Functionalization vinblastine liposome (2.20 ±
0.04)>stearyl-R8The vinblastine liposome (2.09 ± 0.02) of modification>TfR-T12The vinblastine liposome of modification
(2.00±0.12)>Vinblastine liposome (1.65 ± 0.05)>Free vinblastine (1.57 ± 0.03).
4. pro apoptotic protein Bax
Using the expression of pro apoptotic protein Bax in the high intension measure each group cells of Operetta, Columbus is used
System fluorescence intensity in each group is calculated.Bax expression multiple=experimental group fluorescence intensity/blank group fluorescence is strong
Degree.As a result display (Figure 24,1, blank control;2, dissociate vinblastine;3, vinblastine liposome;4, TfR-T12The length of modification
Spring flower alkali liposome;5, stearyl-R8The vinblastine liposome of modification;6, functionalization vinblastine liposome), Bax expression
Sequentially it is:Functionalization vinblastine liposome (1.13 ± 0.03)>TfR-T12Modification vinblastine liposome (1.10 ±
0.02)>stearyl-R8The vinblastine liposome (1.09 ± 0.01) of modification>Vinblastine liposome (1.04 ± 0.03)>
Free vinblastine (1.01 ± 0.03).
5. cromoci (Cytochrome C)
Using the yield of cromoci (Cytochrome C) in the high intension measure each group cells of Operetta, use
Columbus system fluorescence intensity in each group is calculated.Cytochrome C express multiple=experimental group fluorescence
Intensity/blank group fluorescence intensity.As a result display (Figure 25,1, blank control;2, dissociate vinblastine;3, vinblastine liposome;
4, TfR-T12The vinblastine liposome of modification;5, stearyl-R8The vinblastine liposome of modification;6, functionalization catharanthus roseus
Alkali liposome), Cytochrome C order of representation is:Functionalization vinblastine liposome (1.54 ± 0.02)>stearyl-R8
The vinblastine liposome (1.47 ± 0.04) of modification>TfR-T12The vinblastine liposome (1.40 ± 0.04) of modification>It is free
Vinblastine (1.37 ± 0.02)>Vinblastine liposome (1.29 ± 0.04).
6. anti-apoptotic proteins Mcl-1
Using the expression of anti-apoptotic proteins Mcl-1 in the high intension measure each group cells of Operetta, Columbus is used
System fluorescence intensity in each group is calculated.Mcl-1 expression multiple=experimental group fluorescence intensity/blank group fluorescence is strong
Degree.As a result display (Figure 26,1, blank control;2, dissociate vinblastine;3, vinblastine liposome;4, TfR-T12The length of modification
Spring flower alkali liposome;5, stearyl-R8The vinblastine liposome of modification;6, functionalization vinblastine liposome), Mcl-1 tables
Up to being sequentially:Vinblastine liposome (1.03 ± 0.02)>Free vinblastine (0.86 ± 0.03)>TfR-T12The Changchun of modification
Flower alkali liposome (0.85 ± 0.03)>stearyl-R8The vinblastine liposome (0.69 ± 0.02) of modification>Functionalization Changchun
Flower alkali liposome (0.54 ± 0.01).
7. autophagy GAP-associated protein GAP LC3B
Using the expression of autophagy GAP-associated protein GAP (LC3B) in the high intension measure each group cells of Operetta, use
Columbus system fluorescence intensity in each group is calculated.LC3B expresses multiple=experimental group fluorescence intensity/blank
Group fluorescence intensity.As a result display (Figure 27,1, blank control;2, dissociate vinblastine;3, vinblastine liposome;4, TfR-T12
The vinblastine liposome of modification;5, stearyl-R8The vinblastine liposome of modification;6, functionalization vinblastine lipid
Body), LC3B order of representation is:Functionalization vinblastine liposome (1.55 ± 0.05)>stearyl-R8The vinblastine of modification
Liposome (1.48 ± 0.05)>TfR-T12The vinblastine liposome (1.45 ± 0.05) of modification>Vinblastine liposome (1.36
±0.04)>Free vinblastine (1.34 ± 0.05).
8. autophagy GAP-associated protein GAP FoxO1
Using the expression of autophagy GAP-associated protein GAP (FoxO1) in the high intension measure each group cells of Operetta, use
Columbus system fluorescence intensity in each group is calculated.FoxO1 expresses multiple=experimental group fluorescence intensity/sky
White group fluorescence intensity.As a result display (Figure 28,1, blank control;2, dissociate vinblastine;3, vinblastine liposome;4, TfR-
T12The vinblastine liposome of modification;5, stearyl-R8The vinblastine liposome of modification;6, functionalization vinblastine lipid
Body), FoxO1 order of representation is:Functionalization vinblastine liposome (1.14 ± 0.02)>stearyl-R8The vinblastine of modification
Liposome (1.09 ± 0.01)>TfR-T12The vinblastine liposome (1.08 ± 0.02) of modification>Free vinblastine (1.05 ±
0.01)>Vinblastine liposome (1.03 ± 0.01).
The above results show that (1) functionalization vinblastine liposome is respectively provided with most to brain glioblastoma cell and its stem cell
Strong apoptosis induction effect, and apoptosis early stage is mainly reflected in, and apoptosis late period is without significant change;(2) functionalization vinblastine
Cell and and injury of mitochondria maximum of the liposome to brain glioblastoma cell;(3) each group reactive oxygen species order is:Functionalization is grown
Spring flower alkali liposome>stearyl-R8The vinblastine liposome of modification>TfR-T12The vinblastine liposome of modification>Catharanthus roseus
Alkali liposome>Free vinblastine;(4) functionalization vinblastine liposome has micro-pipe in most strong destruction brain glioblastoma cell
Ability;(5) functionalization vinblastine lipid physical efficiency significantly improve pro apoptotic protein caspase-3/7, caspase-8,
Caspase-9, Bax and cromoci (Cytochrome C) level, and anti-apoptotic proteins Mcl-1 level is reduced, simultaneously
Autophagy GAP-associated protein GAP FoxO1 and LC3B expression increase can be caused.
Embodiment 5, anti-glioma and its stem cell effect in nude mouse
First, the foundation and evaluation of lotus glioma nude mice model
1. animal
Only, starting weight is about 18-20g to BALB/c male nude mouses number.
2. cell prepares
Cell is in exponential phase, with cell is resuspended in serum free medium after digestion, is prepared as every 3 μ L containing 2 × 105
Individual U87-MG brain glioblastoma cells, and cell suspension is placed in 4 DEG C of ice baths, it is stand-by.
3. brain glioblastoma cell inoculation method
Using Naoliqing capsule technology, human brain glioma stem cells are inoculated in the cranium brain of BALB/c nude mices, establish brain glue
Matter knurl primary tumor animal model, operating procedure are as follows:
(1) weigh;
(2) anaesthetize, it is fixed:After 4% chloraldurate (1mL/100g) intraperitoneal injection of anesthesia, stereotaxic apparatus is fixed on
On;
(3) sterilization, otch and drilling:It is longitudinal backward along endocanthion line midpoint with 75% alcohol disinfecting mouse skin of vertex
Cut scalp 1cm, exposure skull.According to Naoliqing capsule collection of illustrative plates:1.0mm after bregma, on the right 2.0mm of sagittal suture skull, with
Electric drill drills, and to prevent from puncturing endocranium, only permits drilling through skull depth 1.0-1.5mm;
(4) inoculation human brain glioma stem cells in right caudate nucleus in brain:3.0 μ L gliomas are sucked using 20 μ L micro syringes
Stem cell suspension is (containing about 6 × 105Individual cell), vertical inserting needle depth 3.5mm (away from endocranium), 0.5mm is returned to after standing 1min, with
1 μ L/min speed injects 3.0 μ L cell suspensions in caudate nucleus.Let the acupuncture needle remain at a certain point after injection 5min, slowly pulls out pin, bone hole is used immediately
Bacteria-free bone wax is closed, and visual area normal saline flushing, meets conjunction otch.
Daily regular check its consciousness, haptoreaction, movement defect, cranial nerve lesion, vision response, observation have unbiased
Paralysed, aged and epileptic attack.During Post operation about two weeks, the obvious pathological characters of observable, judge whether to can be used for being administered.
4. model evaluation
After 12 days, 100ml PBS and 100ml 4% is carried out to postanesthetic normal BALB/c male nude mouses and tumor bearing nude mice
Paraformaldehyde cardiac perfusion, take out brain tissue, done otch by inoculation point of puncture and done continuous frozen section (4 μm), and carried out
Nissl's staining, observed using Caikon XDS-300C systems.
Normal observation is carried out to glioma tumor bearing nude mice, it is found that nude mice 0.5h from after being inoculated with brain glioblastoma cell revives.
After operation 5 days, tumor bearing nude mice feed is reduced to be increased with drinking-water, and action is reduced, and body weight gradually mitigates, and bilateral or offside then occurs
Reflection infringement, generally become apparent with hind leg, skin tarnishes;(the about the 10th day) during the late stages of developmet, tumor bearing nude mice is shown as
Face is unclean, in aged face, lassitude, and slow to stimulate the reaction, body depressed neck part, occasionally there is epileptic attack in shape is rolled up.
Internal Brain Glioma Model is evaluated using pathological examination, is as a result shown, normal cerebral tissue (Figure 29) contaminates through Nissl
Visible cell is sparse after color, and each provincial characteristics is obvious;And the brain tissue (Figure 30) for being inoculated with glioma is visible after Nissl's staining
Brain glioblastoma cell dense accumulation in groups, in invasive growth.Illustrate that internal Brain Glioma Model is successfully established.
2nd, the living imaging of tumor bearing nude mice
The preparation of 1.DiR liposomes
Precision weighs each group liposome materials and DiR, by DiR:Fat material=1:500 (w/w) are added in eggplant-shape bottle, dissolving
In the methanol of proper volume, methanol is removed by 40 DEG C of vacuum drying of rotary evaporation, one is formed in eggplant-shape bottle bottom and inwall
The very thin uniform films of layer.Appropriate HEPES buffer solution (10mM, pH7.4,150mM NaCl) is added into eggplant-shape bottle again at 60 DEG C
Aquation 30min in water-bath, room temperature is cooled to, excessive DiR is filtered to remove by 0.2 μm of polycarbonate membrane, produces DiR marks
Targeted hposome.
2. the living imaging in tumor bearing nude mice body
Brain glioblastoma cell is inoculated with after 12 days, the tumor-bearing mice mould for being successfully established Brain Glioma Model is randomly divided into 5 groups,
Every group of 3 difference tail vein injections administration, dosage regimen are as follows:
(1) physiological saline blank control group;
(2) free DiR groups (2.0mg/kg);
(3)TfR-T12The DiR liposomes group (2.0mg/kg) of modification;
(4)stearyl-R8The DiR liposomes group (2.0mg/kg) of modification;
(5) functionalization DiR liposomes group (2.0mg/kg);
1 after administration, 3,6,12,24,48h, utilize IVIS Spectrum Pre-clinical In Vivo Imaging
The functionalization liposome of System investigation DiR marks real-time positioning scenarios in Mice Body.And after 48h, every group of mouse is put to death,
The heart, liver, spleen, lung, kidney and lotus knurl brain tissue are taken out immediately, and different tissues are imaged.
Targeting effect and medicine real-time distribution of the functionalization liposome of DiR marks in glioma tumor bearing nude mice body are such as
Shown in Figure 31, a, physiological saline group;B, dissociate DiR;C, TfR-T12The DiR liposomes of modification;D, stearyl-R8The DiR of modification
Liposome;E, functionalization DiR liposomes.In functionalization DiR liposome groups (Figure 31 e), during 1h, brain fluorescence intensity is maximum, its
He is evenly distributed at position, increases over time, and brain fluorescence slightly weakens, and liver region fluorescence is most strong in 3h, Zhi Housui
Time decrease, other positions have no significant medicine fluorescence;Fluorescence is had no in physiological saline group (Figure 31 a);Free DiR groups
In (Figure 31 b), fluorescence concentrates on liver region, and fluorescence intensity is increased over time and strengthened, and brain has no fluorescence;TfR-T12
The DiR liposome groups (Figure 31 c) and stearyl-R of modification8In the DiR liposome groups (Figure 31 d) of modification, brain has certain
Fluorescence, liver region fluorescence intensity is maximum, and other positions also have certain fluorescence.
The functionalization liposome of DiR marks drug distribution when glioma tumor bearing nude mice respectively organizes 48h is as shown in figure 32,
A, physiological saline group;B, dissociate DiR;C, TfR-T12The DiR liposomes of modification;D, stearyl-R8The DiR liposomes of modification;E,
Functionalization DiR liposomes.In each group, functionalization DiR liposome group (Figure 32 e) deutocerebral region fluorescence is most strong, TfR-T12The DiR of modification
Liposome group (Figure 32 c) deutocerebral region also has strong fluorescence, stearyl-R8DiR liposome group (Figure 32 e) deutocerebral region of modification
With week fluorescent, free DiR group (Figure 32 b) deutocerebral region of physiological saline group (Figure 32 a) has no fluorescence.Except physiological saline group, its
Remaining each group center, liver, spleen, lung, kidney have certain fluorescence, but mainly concentrate on liver.
3rd, the anti-glioma effect in tumor bearing nude mice body
1. life cycle is investigated
Brain glioblastoma cell is inoculated with after 12 days, the tumor-bearing mice mould for being successfully established Brain Glioma Model is randomly divided into 6 groups,
Every group of 9 difference tail vein injections administration, dosage regimen are as follows:
(1) physiological saline blank control group;
(2) free vinblastine group (50 μ g/kg);
(3) vinblastine liposome group (50 μ g/kg);
(4)TfR-T12The vinblastine liposome group (50 μ g/kg) of modification;
(5)stearyl-R8The vinblastine liposome group (50 μ g/kg) of modification;
(6) functionalization vinblastine liposome group (50 μ g/kg);
Give a medicine within every three days, be administered three times altogether.After administration, every group takes 9 mouse, and tumor bearing nude mice behavior state is entered daily
Row observation, records its activity situation, symptom, date of death, investigates survivorship curve.Draw Kaplan-Meier survivorship curve
(Kaplan-Meier survival curves), and calculate life span median (the median survival
Times, MeST) and life span average value (the mean survival times, MST).Life cycle is calculated as follows
Increase percentage (the percentage-increased life span, ILS%):
t:Represent the nude mice for receiving treatment, U:Represent the nude mice for not receiving treatment.
Figure 33 is that glioma tumor bearing nude mice receives the Kaplan-Meier survivorship curve after each preparation group treatment, and a is raw
Manage salt solution group;B, vinblastine group of dissociating;C, vinblastine liposome group;D, TfR-T12The vinblastine liposome group of modification;
E, stearyl-R8The vinblastine liposome group of modification;F, functionalization vinblastine liposome group.As a result show, functionalization length
Spring flower alkali liposome group has maximum median survival interval (29 days), and 52.63% is added than physiological saline group (19 days).This
Outside, compared with physiological saline group, free vinblastine group (20 days) adds 5.26%, and vinblastine liposome group increases for (21 days)
10.53%, TfR-T is added12The vinblastine liposome group (26 days) of modification adds 36.84%, stearyl-R8Modification
Vinblastine liposome group (27 days) adds 42.11%.As a result show, compared with control formulation, functionalization vinblastine fat
Plastid can significantly improve the therapeutic action to glioma tumor bearing nude mice brain tumor.
2. anti-human brain glioma stem cells effect in body
After being inoculated with brain glioblastoma cell and drug treatment according to the method described above, physiological saline blank control group, catharanthus roseus are taken
Alkali liposome group and each three of functionalization vinblastine liposome group tumor bearing nude mice, not to be inoculated with the healthy naked of brain glioblastoma cell
Mouse is negative control group, through physiological saline and 4% paraformaldehyde cardiac perfusion after anesthesia, take out brain tissue (while take out the heart,
Liver, spleen, lung, kidney are standby), sucrose dehydrated overnight.By mouse brain surface seeding point of puncture as otch, continuous frozen section (4 is done
μm)。
Section is dipped in 0.2%Triton X-100 solution after 30min progress Cell-transmission model, is transferred to containing 10% goat
5h is closed in the PBS solution of serum, with anti-nestin antibody (1:100 dilutions) it is incubated overnight under the conditions of 4 DEG C, then
With anti-rabbit secondary antibody conjugated with Alexafluor-488 (1:500 dilutions) and
Hoechst 33342 ((5 μ g/mL)) is incubated 1h.Glioma in observation each group is carried out using laser confocal scanning microscope
Stem cell situation.
Immunofluorescence dyeing is carried out using stem cell labeling thing nestin, to evaluate tumor bearing nude mice brain brain glue after administration
The quantity of matter knurl stem cell.Immunofluorescence dyeing result is as shown in figure 34, a, normal cerebral tissue;B, the lotus brain of injecting normal saline
Glioma brain tissue;C, inject the lotus glioma brain tissue of vinblastine liposome;D, function of injection vinblastine lipid
The lotus glioma brain tissue of body, blue-fluorescence is the nucleus dyed by Hoechst 33342, by thin to all brain tissues
Born of the same parents' mark sketches the contours of full brain form;Green fluorescence is nestin pigmented sections, can serve to indicate that human brain glioma stem cells.From figure
In as can be seen that Normal brain cortical tissue (not being inoculated with brain glioblastoma cell) region, nucleus is evenly distributed and more sparse;
And tumor tissue sections, nucleus distribution are fine and close, it is seen that glioma region.The therapeutic effect of each preparation group, Ke Yiyong
Nestin expression region accounts for the ratio in full brain area domain as evaluation criterion.As a result show, in functionalization vinblastine liposome group,
The fluorescence area marked by nestin is minimum, in Local map, it was observed that tumour cell is less and distribution is sparse;And in physiology salt
In water group, the fluorescence area marked by nestin is larger, has accounted for the area of right brain about half, and cell is more in Local map
It is intensive;In vinblastine liposome, the fluorescence area marked by nestin is more compared with functionalization vinblastine liposome group, and in brain
Portion to form two focuses there occurs transfer, and Local map shows that cell is very intensive.Anti- glioma is dry thin in vivo for each preparation group
Born of the same parents' effect is ordered as:Functionalization vinblastine liposome group>Vinblastine liposome group>Physiological saline group.
4th, safety evaluatio
The paraformaldehyde of above-mentioned middle the taken heart, liver, spleen, lung, nephridial tissue 4% is fixed, is prepared as paraffin section (4 μ
M), HE (hematoxylin-eosin) dyeing is carried out, and utilizes the observation of Caikon XDS-300C systems.
As a result as shown in figure 35, a, physiological saline group;B, functionalization vinblastine liposome group and physiological saline group it is each
Tissue HE coloration results compare, and respectively tissue obvious pathological change to functionalization vinblastine liposome group nude mice does not occur.
In summary, through functional vector material TfR-T12-PEG2000- DSPE and stearyl-R8The function of modification simultaneously
Changing liposome has most obvious tumor region drug accumulation and most strong anti-glioma and human brain glioma stem cells effect, energy
Dramatically increase the life span of tumor bearing nude mice.
Claims (10)
1. a kind of liposome or vinblastine liposome,
The liposome is poly- through TfR binding peptide-PEG2000-DSPE and stearyl eight
Arginine is modified;
The vinblastine liposome is by the liposome and contains the vinblastine in the liposome and forms;
TfR binding peptide-the PEG2000-DSPE is by TfR-T12Polypeptide and NHS-
PEG2000The product that-DSPE is obtained by acid amides key connection.
2. a kind of method for preparing vinblastine liposome described in claim 1, for TfR binding peptide-poly- second two
Alcohol-DSPE and the poly arginine modified liposome of stearyl eight, and vinblastine is contained in the fat
Vinblastine liposome is obtained in plastid.
3. according to the method for claim 2, it is characterised in that:Methods described comprises the following steps:
1) TfR binding peptide-PEG2000-DSPE is prepared;
The preparation method comprises the following steps:By TfR-T12Polypeptide and NHS-PEG2000- DSPE enters in the presence of catalyst
Row acylation reaction, obtain TfR binding peptide-PEG2000-DSPE;
2) with lecithin, cholesterol, TfR binding peptide-PEG2000-DSPE and
The poly arginine of stearyl eight carries out film formation reaction, liposome after being modified, liposome after being modified;
3) vinblastine is contained after the modification in liposome, obtains vinblastine liposome.
4. according to the method for claim 3, it is characterised in that:
In step 1), the TfR-T12Polypeptide and NHS-PEG2000- DSPE molar ratio is 1:1-3:1;
Or, the catalyst is N-methylmorpholine;
Or, the catalyst and the TfR-T12The charge ratio of polypeptide is 200 μ L:8μmol;
Or, the temperature of the acylation reaction is normal temperature, the time of acylation reaction is 48h;
Or, the acylation reaction is carried out in a solvent;
Or, the solvent is specially DMF.
5. the method according to claim 3 or 4, it is characterised in that:
In step 2), the lecithin, cholesterol, institute's TfR binding peptide-polyethylene glycol-distearoylphosphatidyl second
The molar ratio of hydramine and the poly arginine of the stearyl eight is 60:30:3:5.
6. according to any described method in claim 3-5, it is characterised in that:
In step 3), the mass ratio that feeds intake of liposome is 1 after the vinblastine and the modification:20.
7. the TfR binding peptide-polyethylene glycol-two being prepared in claim 3-6 in any methods described
Stearyl phosphatidyl monoethanolamine;
Or liposome after the modification being prepared in claim 3-6 in any methods described.
8. TfR binding peptide-PEG2000-DSPE described in claim 6 is preparing fat
Plastid prepares vinblastine liposome or modified liposome or the application modified in vinblastine liposome;
Or the vinblastine liposome described in claim 1 or the TfR binding peptide described in claim 6-poly- second two
Alcohol-DSPE is being prepared with following 1) -9) application in the product of at least one function:
1) brain glioblastoma cell or its stem cell are killed;
2) brain glioblastoma cell or its stem cells hyperplasia are suppressed;
3) blood-brain barrier is crossed over;
4) brain glioblastoma cell or its stem cell apoptosis are promoted;
5) brain glioblastoma cell or the injury of mitochondria of its stem cell are promoted;
6) brain glioblastoma cell or its Stem Cell Activity oxygen level are improved;
7) brain glioblastoma cell or the micro-duct injury of its stem cell are promoted;
8) improve and promote apoptosis-related protein gene expression in brain glioblastoma cell or its stem cell;
9) prevent and/or treat glioma.
9. one kind has following 1) -9) product of at least one function, its active component is the vinblastine described in claim 1
Liposome;
1) brain glioblastoma cell or its stem cell are killed;
2) brain glioblastoma cell or its stem cells hyperplasia are suppressed;
3) blood-brain barrier is crossed over;
4) brain glioblastoma cell or its stem cell apoptosis are promoted;
5) brain glioblastoma cell or the injury of mitochondria of its stem cell are promoted;
6) brain glioblastoma cell or its Stem Cell Activity oxygen level are improved;
7) brain glioblastoma cell or the micro-duct injury of its stem cell are promoted;
8) improve and promote apoptosis-related protein gene expression in brain glioblastoma cell or its stem cell;
9) prevent and/or treat glioma.
10. the product described in application according to claim 8 or claim 9, it is characterised in that:The rush apoptosis is related
Albumen is caspase-3/7, caspase-8, caspase-9, Bax, cromoci, Mcl-1, LC3B or FoxO1;
Or the product is medicine or kit.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610854962.2A CN107875123B (en) | 2016-09-27 | 2016-09-27 | Functionalization vinblastine liposome and its application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610854962.2A CN107875123B (en) | 2016-09-27 | 2016-09-27 | Functionalization vinblastine liposome and its application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107875123A true CN107875123A (en) | 2018-04-06 |
CN107875123B CN107875123B (en) | 2019-07-16 |
Family
ID=61768677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610854962.2A Expired - Fee Related CN107875123B (en) | 2016-09-27 | 2016-09-27 | Functionalization vinblastine liposome and its application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107875123B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108853513A (en) * | 2018-07-09 | 2018-11-23 | 荆楚理工学院 | A kind of target liposomes and preparation method thereof with pH and temperature dual responsiveness |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1795859A (en) * | 2004-12-27 | 2006-07-05 | 北京文卓医药生物制品技术开发有限公司 | Alkaloid liposome in vinca and production technique |
CN101816629A (en) * | 2009-02-26 | 2010-09-01 | 北京大学 | Dual target liposome and preparation method and application thereof |
CN105708802A (en) * | 2016-03-24 | 2016-06-29 | 石河子大学 | Casticin lung-targeted liposome and preparation method and application thereof |
-
2016
- 2016-09-27 CN CN201610854962.2A patent/CN107875123B/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1795859A (en) * | 2004-12-27 | 2006-07-05 | 北京文卓医药生物制品技术开发有限公司 | Alkaloid liposome in vinca and production technique |
CN101816629A (en) * | 2009-02-26 | 2010-09-01 | 北京大学 | Dual target liposome and preparation method and application thereof |
CN105708802A (en) * | 2016-03-24 | 2016-06-29 | 石河子大学 | Casticin lung-targeted liposome and preparation method and application thereof |
Non-Patent Citations (1)
Title |
---|
LI QIN ET AL.: "A dual‑targeting liposome conjugated with transferrin and arginine‑glycine‑aspartic acid peptide for glioma‑targeting therapy", 《ONCOLOGY LETTERS》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108853513A (en) * | 2018-07-09 | 2018-11-23 | 荆楚理工学院 | A kind of target liposomes and preparation method thereof with pH and temperature dual responsiveness |
Also Published As
Publication number | Publication date |
---|---|
CN107875123B (en) | 2019-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cui et al. | Hacking macrophage-associated immunosuppression for regulating glioblastoma angiogenesis | |
Johng et al. | Use of magnetic nanoparticles to visualize threadlike structures inside lymphatic vessels of rats | |
Lakkadwala et al. | Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma | |
CN100374550C (en) | Magnetic cell and method of using the same | |
CN101816629B (en) | Dual target liposome and preparation method and application thereof | |
Liu et al. | Enhancing magnetic resonance/photoluminescence imaging-guided photodynamic therapy by multiple pathways | |
CN108042805A (en) | A kind of tumour carries medicine microparticle preparation and preparation method thereof | |
CN106333926A (en) | Brain tumor multiple targeting drug delivery system of stability polypeptide mediated cross-barrier film | |
CN107802646A (en) | A kind of anti-tumor medicine | |
CN108685875A (en) | A kind of natural nano grain-pharmaceutical composition of anti-alzheimer's disease and its preparation method and application | |
Wei et al. | A novel delivery system of cyclovirobuxine D for brain targeting: Angiopep-conjugated polysorbate 80-coated liposomes via intranasal administration | |
CN103830739B (en) | The delivery system and application thereof that ligand polypeptide PH1 is formed | |
CN109745326A (en) | A kind of pharmaceutical composition comprising Gefitinib and inhibitors of histone deacetylase, Liposomal formulation and its pharmaceutical applications | |
Yao et al. | An MRI-guided targeting dual-responsive drug delivery system for liver cancer therapy | |
CN107875123B (en) | Functionalization vinblastine liposome and its application | |
Li et al. | Cell penetrating peptide modified M2 macrophage derived exosomes treat spinal cord injury and rheumatoid arthritis by loading curcumin | |
CN109453117A (en) | Cardiac glycosides active ingredient composite lipidosome and preparation method thereof | |
CN107432875A (en) | It is a kind of to be used to treat functional motor ability plastid of lung neoplasm and preparation method and application | |
CN105770912B (en) | Load medicine ATP sensitive liposome with tumour near-infrared fluorescent image displaying function and preparation method thereof | |
Sun et al. | Smart composite scaffold to synchronize magnetic hyperthermia and chemotherapy for efficient breast cancer therapy | |
Deng et al. | Exchangeability of FITC-SiO2 nanoparticles between cancer cells increases the range of drug delivery | |
Loai et al. | Three‐Dimensional Bioprinted MR‐Trackable Regenerative Scaffold for Postimplantation Monitoring on T1‐Weighted MRI | |
CN104224718B (en) | A kind of multifunctional targeted vinorelbine liposome and preparation method thereof | |
CN109674741A (en) | Pharmaceutical carrier and preparation method thereof | |
Cheng et al. | The potential of novel synthesized carbon dots derived resveratrol using one-pot green method in accelerating in vivo wound healing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190716 |